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Thanks to the development of antiretroviral treatment (ART), human immunodeficiency virus 
(HIV) infection is now considered a chronic infection rather than the death sentence it used to 
be. Despite constant expansion and improvement of treatment options, even optimal therapy 
cannot prevent the impact of HIV on the human immune system. Persistence of latently 
infected cells, low-level residual viral replication and long-term impact from initial tissue 
damage lead to chronic immune activation, which in turn drives a number of comorbidities 
and complications that lower the patient´s quality of life. 
The hallmark of HIV infection is the depletion of CD4 T cells, also called helper T cells. In 
addition to immune activation due to the virus itself, the lack of support by CD4 T cells 
impairs numerous immune cell types. As the main defender against viral infections, CD8 T 
cells play a central role in ending the peak of viral replication during acute HIV infection. 
However, during the subsequent chronic phase, they become exhausted, which impairs not 
only immune responses against HIV, but also other viral infections and malignant cells. 
In paper I we investigate the role of the immune receptor TIGIT in HIV type 1 (HIV-1) 
infection. As an exhaustion marker, it is increased in HIV-1 infection, co-expressed with 
other inhibitory receptors and fails to return to normal levels despite viral suppression by 
ART. It is also part of a regulation network together with the complementary co-stimulator 
CD226 and their shared ligand PVR. All members of this network are skewed in HIV-1 
infection and contribute to CD8 T cell exhaustion and immune deterioration. 
Of the few human genetic factors beneficial in HIV-1 infection, HLA-B*57 has the potential 
to slow down disease progression. Paper II investigates the connection between HLA-B*57 
and exhaustion of HIV-specific CD8 T cells. Delayed co-expression of TIGIT and PD-1 
might be one factor contributing to slower disease progression often seen in people positive 
for the HLA-B*57 allele. 
HIV type 2 (HIV-2) is associated with slower disease progression and a higher chance of 
virus control by the host immune system than HIV-1. In paper III, we found signs of CD8 T 
cell pathogenesis, especially a skewed balance of co-stimulation and inhibition, in HIV-2 
infection despite controlled viral replication. 
HIV-1 pathogenesis in children after mother-to-child transmission shows differences from 
pathogenesis in adult patients and leads to unique complications. To better understand the 
unique aspects of pediatric HIV infection and potentially find candidates for therapeutic 
intervention, we investigated plasma biomarkers in well treated children in paper IV. Their 
treatment prevents high levels of dysregulation in comparison to HIV-negative children. 
However increased levels of sTRAIL, a marker for T cell activation with potential to induce 
apoptosis, shows the capacity to further optimize treatment in HIV infected children.  
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1.1 THE HUMAN IMMUNODEFICIENCY VIRUS PANDEMIC 
1.1.1 Epidemiology and current status 
Awareness of acquired immunodeficiency syndrome (AIDS) first arose in the early 1980ies, 
starting with the report about five cases of pneumonia in previously healthy men who have 
sex with men (MSM) by physicians in Los Angeles (1). Following this, more cases of 
pneumonia, Kaposi´s Sarcoma and other opportunistic infections were reported from the 
MSM community, drug users and recipients of blood transfusions. Epidemiologists urged for 
surveillance of new cases, defined risk groups and revealed routes of transmission. Important 
research advances were the isolation of the causative agent, the human immunodeficiency 
virus (HIV), in 1983 (2), the development of diagnostic tests (3, 4) and cloning, as well as 
sequencing of the viral genome (5-7). 
Analysis of viral genomes revealed that HIV was a zoonotic infection that crossed the species 
barrier between chimpanzees and humans (8, 9). Urbanization, colonization, increased 
transcontinental travelling, and other human behaviors allowed the virus to disseminate 
globally and lead to manifestation of the HIV/AIDS pandemic with increasing rates of HIV 
infections until 1998. Since then, the development of antiretroviral drugs targeting different 
steps in the HIV replication cycle, effective combination therapy, and global efforts to 
diagnose and treat HIV have reduced the rate of new infections. Simultaneously, the 
improved access to and quality of medical care prolonged the survival of people living with 
HIV (PLHIV) to almost normal life spans. 
According to UNAIDS estimations, 38 million people lived with an HIV infection in 2019, 
1.8 million of which are children younger than 15 years. 1.7 million were newly infected in 
2019, 150 000 of which were children. Of the PLHIV that knew about their infection, 66.8% 
had access to antiretroviral treatment (ART) (10). This number is even lower among children, 
where only 53% of infected individuals received ART. 690 000 PLHIV died of AIDS-related 
causes in 2019. Despite great success, this is still considerably higher than the intended 
reduction below 500 000 deaths by 2020. Global institutions have expressed the goal to 
diagnose 90% of PLHIV, provide ART to 90% of diagnosed individuals and achieve viral 
suppression in 90% of treated PLHIV by 2020. This 90-90-90 target has been achieved in a 
number of countries, among which Sweden was the first by accomplishing the goal in 2015 
(11). 
1.1.2 Viral diversity and global distribution 
HIV belongs to the genus Lentivirus, within the family of Retroviridae. Today, two types of 
HIV are known, HIV type 1 (HIV-1) and HIV-2. HIV-1 comprises four groups (M - major, O 
– outlier, N - non-M/non-O and P). The global HIV pandemic is caused by HIV-1 group M. 
HIV-2 is relatively confined to Western Africa and countries with social and economic 
 
2 
connections to this region. HIV-2 is considered a “mild” form of HIV due to slower disease 
progression and lower transmission rates. 
One reason for the phylogenetic diversity of HIV is the zoonotic origin. In old world 
monkeys, more than 40 different simian immunodeficiency viruses (SIV) are known. SIV 
infections typically occur within the same monkey species and, as a result of co-evolution of 
virus and host, cause mild to no disease. HIV-2 is the result of eight transmissions from sooty 
mangabeys to humans (12), resulting in 8 lineages. In contrast, SIV of chimpanzees (SIVcpz) 
developed from two monkey SIV clades that recombined after transmission from their 
original hosts to chimpanzees. After transmission to humans, SIVcpz disseminated as HIV-1 
group M and N. SIVcpz also crossed into gorillas, creating SIVgor and subsequently HIV-1 
group P and O (12, 13). Since the dissemination of HIV-1 group M, it has diversified into 
several subtypes or clades (A, B, C, D, F, G, H, J and K) as well as circulating recombinant 
forms (CRFs). The dissemination of these subtypes differs vastly between the continents. 
Subtype B is the most prevalent virus in North America, Australia, the majority of Europe 
and parts of South America. Subtype C is prevalent in the South-East of Africa and India, 
while other parts of the world, especially sub-Saharan Africa, show a more complex 
distribution of two or more subtypes and CRFs (14).  
1.1.3 Transmission routes of HIV 
HIV transmissions can occur via sexual contact, parenteral via blood or cerebral spinal fluid, 
and through mother-to-child transmission (MTCT) during pregnancy, birth or breastfeeding. 
Depending on the type of exposure, the transmission risk can vary from 0.08% per exposure 
from insertive heterosexual intercourse (15) up to more than 90% from transfusion of infected 
blood (16).  
While the original transmission between monkeys or apes to humans is believed to be the 
result of contact with infected blood when hunting the animals, the dissemination of HIV-1 
group M was enabled by migration from rural areas to Kinshasa (17). Heterosexual 
transmission, in particular through sex workers, as well as the use of unsterile needles 
resulted in fast dissemination of the virus. From Kinshasa, the virus spread to the Caribbean 
and subsequently to North America, where it was already present in the 1970s (18), but went 
undetected for another decade. As the resulting disease, AIDS, was first discovered in MSM 
in the early 1980s, it was initially associated with homosexual transmission. However, use of 
unsterile needles among intravenous drug users (IVDU) and use of blood products in health 
care interventions substantially contributed to establishment of the pandemic. While 
screening of blood donations and improvement of hygiene practices has virtually eliminated 
the risk of HIV infection via health care systems, there is still a large difference in the mode 
of HIV transmission between different parts of the world. In Western and Central Europe as 
well as North America 64% of HIV transmissions are related to MSM. Similarly, this is the 
most common transmission route in Latin America, Asia and the Pacific. However, in these 
regions, 25 - 30% of new infections are related to either sex work or partners of people at 
high risk. In the Middle East, North Africa, eastern Europe and central Asia, people who 
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inject drugs are at the highest risk of HIV infections. This is a stark contrast to eastern and 
southern Africa, where only 28% of all HIV transmissions can be attributed to risk groups. 
In order to reduce transmission rates, numerous organizations offer programs ranging from 
large scale awareness campaigns for the general public to national efforts such as needle 
exchange programs for IVDUs. One area of great success is the prevention of MTCT. HIV 
testing of pregnant women and administration of ART to infected mothers during pregnancy 
and breastfeeding have radically decreased the number of MTCTs globally and more 
specifically in Africa (19). The remaining MTCTs are often linked to particularly vulnerable 
groups, such as young women with little access to health care systems, insufficient education, 
experiencing violence and stigma, or similar social and economic problems (10). Similarly, 
HIV infected children not receiving ART often belong to particularly vulnerable populations, 
such as orphans of HIV infected parents, or were never tested for HIV despite having infected 
family members. 
1.2 NATURAL COURSE OF HIV INFECTION 
1.2.1 Transmission and acute infection 
HIV particles can be detected in blood, semen, pre-seminal, vaginal and rectal fluid as well as 
breast milk (20). Via abrasions or lesions in mucosa or skin, HIV can enter submucosal tissue 
and is typically taken up by dendritic cells (DCs) as they patrol the tissue (21). DCs then 
transport the virus to lymphoid tissue, where large quantities of CD4 helper T cells are 
present. As these CD4 T cells are the main target cells for HIV infection, lymph nodes are a 
major site for HIV establishment, spread, and persistence. Alternatively, CD4 T cells can be 
infected at the site of HIV entry, if they are present either as tissue resident cells, have 
recently entered the already inflamed site, or if HIV contaminated fluids come into direct 
contact with circulating blood. Inflamed lesions due to other pathogens facilitate HIV 
infection by destruction of the mucosal barrier and recruitment and activation of immune 
cells. This biological mechanism explains why other sexually transmitted diseases are often 
risk factors for HIV infection (22). 
As an enveloped virus, HIV is surrounded by the cell membrane from an infected host cell, 
which contains the viral envelope glycoprotein (Env). Upon contact with the target cell, Env 
consecutively binds to two receptors, the main receptor CD4 (23, 24) and a co-receptor (25-
28). CD4 is expressed by T cells and monocytes/macrophages, and binding to CD4 on the 
target cell leads to conformational changes of Env, bringing the virion closer to the cell. This 
change also exposes the binding site for the co-receptor, which in the majority of HIV 
transmissions is C-C chemokine receptor type 5 (CCR5). Alternatively, HIV can mutate to 
bind to C-X-C motif chemokine receptor 4 (CXCR4) as a co-receptor, which is usually 
associated with later disease stages (28). The particles can thus be classified into R5- or X4-
tropic virus. In contrast to HIV-1, HIV-2 can bind to a multitude of co-receptors (29). 
Binding to the co-receptor initiates membrane fusion and release of the inner components of 
HIV virions into the cytoplasm. HIV particles contain a conical core of capsid protein 
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encasing two positive sense, single-stranded RNA molecules and three viral proteins: reverse 
transcriptase (RT), integrase (INT) and protease (PR). RT synthesizes complementary DNA 
from the RNA template, the step in their life cycle that retroviruses are named for. The 
enzyme lacks proof-reading ability, resulting in a high rate of mutations per replication. INT 
subsequently incorporates the viral DNA into the human genome. For synthesis of messenger 
RNA (mRNA) and viral proteins, the virus hijacks the host cell transcriptional and 
translational machinery. HIV, as many other viruses, minimizes it´s genome size by using 
several open reading frames and encoding polyproteins, that then need to be cleaved by PR or 
a cellular protease into their functional protein subunits. From the structural proteins and 
RNA, HIV virions assemble and, after budding off their cell of origin, infect their next target 
cell. In addition to the building blocks for new virions, i.e. the structural proteins, HIV also 
possesses a number of accessory proteins, some of which interact with host proteins to evade 
the immune system, others regulate viral gene expression. 
 
Figure 1. Progression of plasma viral load, CD4 and CD8 T cell counts in HIV infection. 
Re-printed with permission from (30). 
As T cells enter circulation, HIV disseminates rapidly throughout the human body, especially 
lymphoid tissues. Consequently, a high number of cells are infected, resulting in a high virus 
concentration in blood, both as free virions (31), and as infected cells (32). As a quickly 
disseminating cytopathic virus, HIV causes a sudden depletion of its target cells, CD4 T cells 
(Fig. 1). A large proportion of human CD4 T cells resides in the intestinal lamina propria and 
gut associated lymphoid tissues (GALT) (33), creating an optimal hotspot for HIV replication 
and CD4 T cell depletion during peak viremia. CD4 T cells are not merely residing in the gut, 
but are integral to homeostasis and barrier function (34). The depletion of more than 70% of 
intestinal CD4 T cells, especially the subset of Th17 cells (35), during primary HIV infection 
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components like lipopolysaccharide (LPS) to reach the circulation, a process called microbial 
translocation (37) and a driving force behind activation and exhaustion of the cellular 
immune system. Similarly, both the thymus and lymph nodes, essential for renewal and 
maintenance of the CD4 T cell pool, suffer from structural destruction. Reduced thymic 
function impairs production of naïve T cells (38, 39) and thus contributes to loss of CD4 T 
cells beyond cytopathic effects (40). Insufficiently replacement of Th17 cells links loss of 
thymic function to microbial translocation. 
On average 14 days after infection, the rapid increase of viral replication can cause symptoms 
typically associated with viral infections, such as fever, pharyngitis, rash, diarrhea, and 
general weakness. Approximately three weeks after symptom onset, the peak viral load and 
initial CD4 T cell depletion is in part controlled by the development of HIV-specific CD8 T 
cells (Fig. 1) (41). The importance of this cell type was first seen in in vitro experiments (42) 
and later confirmed using SIV-infected monkeys depleted of CD8 T cells (43). Without CD8 
T cells, the immune system fails to end the increase in viral replication and infection of new 
target cells, accelerating mortality in the monkeys. Despite ending peak viremia, the immune 
response against HIV is not capable of completely eliminating the virus and HIV establishes 
a chronic infection.  
Furthermore, B cells develop HIV-specific antibodies. B cells become highly activated and 
develop neutralizing antibodies against HIV in the vast majority of patients. However, HIV 
escapes antibody responses with escape mutations and by shielding HIV Env with glycans. 
Furthermore, HIV decreases the quality of antibody responses over time by exhausting and 
dysregulating B cell responses. 
1.2.2 Chronic Infection 
Already the first report of HIV in 1981 noted the deficiency of the cellular immune system 
seen in HIV infected individuals, which was soon connected to the depletion of CD4 T cells. 
Thus, two parameters, plasma viral load (VL; number of RNA copies per mm3 plasma) and 
CD4 T cell count (number of CD4 T cells per mm3 blood), became the standard way to 
monitor patients with regards to disease progression.  
After the acute stage of HIV infection, CD4 T cells can recover partially (44), but over the 
course of the subsequent chronic phase, CD4 T cell depletion continues at a slow rate (Fig. 
1). A few weeks to months after infection, the viral load reaches a more or less stable level, 
termed the viral set point. The viral set point is indicative of the rate of disease progression 
(45), which is highly variable between individuals. A very small group of patients, so-called 
elite controllers, can suppress viral replication below standard detection limits over several 
years. Another group, often called viremic controllers, suppress viral load below usual levels, 
but above detection limit. In contrast, long-term non-progressors (LTNPs) are defined by 
their maintenance of CD4 T cells regardless of viral load. Despite commonly used terms, the 
exact values (VL, CD4 T cell count, and duration of control/maintenance) used to define 
these categories can change between studies. However, the vast majority of untreated HIV 
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infections progress to AIDS within less than 10 years, and rapid progressors can experience 
AIDS within a year or less after infection (46).  
During chronic infection, the persistence of viral antigen leads to immune activation and low 
inflammation, which in turn fuels immunosenescence (47). The replication capacity of the 
HIV founder virus (48), the virus that established HIV infection in a host, influences the 
severity of immune activation. Furthermore, co-infections contribute to the immune 
activation (49) and the damage to lymphoid tissues progresses during chronic infection and 
exacerbates immune dysregulation. 
HIV causes CD4 T cell depletion not only directly through cytopathogenicity of infected 
cells, but also by cell death of bystander cells (50). A highly inflammatory type of cell death, 
pyroptosis, is common in HIV infection (51). As a result of pyroptosis, cytoplasmic content 
of the dying cell and cytokines are released, which serve as additional proinflammatory 
signals. In addition to cell death, regeneration of CD4 T cells is compromised. Thymic 
function, essential for T cell development, is impaired (38) and infection of progenitor cells 
(52) abrogates their potential to proliferate and thus maintain CD4 T cell numbers. 
PLHIV typically do not experience symptoms during the chronic stage HIV infection. 
However, without ART initiation and adherence, HIV infection progresses to AIDS as CD4 T 
cell counts become insufficient to maintain host defense. 
1.2.3 Antiretroviral therapy 
In 1987, the first drug against HIV, azidothymidine (53), which is now called zidovudine, 
was licensed. As a nucleoside reverse transcriptase inhibitor (NRTI), it targets the viral 
reverse transcriptase and prevents synthesis of DNA from the viral RNA template. The drug 
resulted in a temporary reduction of viral replication, but drug resistances developed rapidly 
due to the high mutation rate and virion production of HIV (54). Further NRTIs were 
developed in the following years, but only with the first protease inhibitor (PI), approved as 
Saquinavir in 1995, was it possible to target a different step in the HIV life cycle. Major 
improvement in the form of durable suppression of viral replication was achieved by the 
introduction of combination therapy (55, 56), using two NRTIs together with one PI. Triple 
therapy has since been standard in the treatment of PLHIV. Over the years, non-nucleoside 
reverse transcriptase inhibitors (NNRTIs) as well as entry, fusion and integrase inhibitors 
expanded the repertoire of HIV drugs (57). Thus, through modern ART we can effectively 
inhibit viral entry, replication and maturation but not neutralize virions or eliminate latently 
infected cells. 
In addition to HIV infection resulting in virus production by infected cells, it also leads to 
latent infection where HIV stays dormant inside long-lived memory T cells (58), myeloid 
cells and probably hematopoietic progenitor cells (59). Because these latently infected cells 
cannot be targeted by current ART, they make up the viral reservoir in treated PLHIV and 
spontaneously re-establish infection once ART is discontinued (60). Only a small proportion 
of patients that initiated ART very early in HIV infection can develop post-treatment control 
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(61), a phenomenon without clear definitions regarding the extent of viral load suppression or 
duration of control. It is unclear whether latent infection is established by infection of active 
CD4 T cells and escape from cell death when transitioning to a resting state (62), or whether 
HIV is indeed capable of infecting resting memory cells (63). However, sequence analysis of 
the viral reservoir revealed that it is established very early and continues to grow throughout 
the infection (64).  
In addition to latently infected cells, HIV maintains low levels of viral replication even after 
years of viral suppression by ART (65). Incomplete drug penetrance into specific anatomical 
sites, e.g. lymph nodes or the central nervous system, allows viral replication and 
consequential de novo infection (66, 67).  
Until 2015, treatment was initiated when CD4 T cell counts reached a certain level, which 
changed as new evidence was reported (e.g. 500 cells/mm3 was the recommended threshold 
for initiation from 2013 to 2015). However, earlier treatment was linked to improved 
outcome, leading to the current recommendation to start treatment upon diagnosis, regardless 
of CD4 T cell count (68). Corresponding to the clinical monitoring of CD4 T cell counts and 
VL, two outcomes define successful ART: suppression of VL below detection limits and 
reconstitution of CD4 T cell counts. Virological failure is defined as failing to achieve or 
sustain VL below 200 copies/mL (69) and testing for resistance mutations typically guides 
medication change, though problems in adherence, drug absorption or interactions with other 
drugs can be alternative explanations (70). In contrast, there is no uniform definition for 
immunological failure and different thresholds of CD4 T cell count, % CD4 T cells (CD4%), 
or increase in CD4 T cell count above pre-treatment baseline are used (71). The cause for 
immunological failure is also not straightforward, usually including several factors impacting 
production or depletion of CD4 T cells. However, choice of the optimal ART regimen has the 
potential to aid immune recovery (72).  
As seen for early monotherapy, HIV quickly develops drug resistance when given the 
opportunity to replicate under suboptimal concentrations of the drugs. Viral replication 
despite treatment due to problems in ART adherence or access, and inadequate treatment due 
to undiagnosed virological failure are the main reasons for acquired drug resistance. 
However, virus with established resistance mutations is commonly less fit than drug sensitive 
sequences and after discontinuing ART the proportion of circulating resistant virus declines 
(73). The increased access to ART under suboptimal conditions increases the occurrence of 
transmitted drug resistance (74) and as long as vaccines or a cure for HIV remain elusive, 
resistance will pose an increasing challenge in the fight against the HIV pandemic. In the 
meantime, the continued spread of HIV is addressed with strategies like pre-exposure 
prophylaxis (75), or development of antiretroviral microbicides administered as vaginal gels 
(76). Furthermore, adherence problems, and thus resistance, could be limited by 
administration of long acting ART (77). 
Adverse effects due to ART toxicity include dermatologic manifestations such as rash, 
neurotoxicity, hepatotoxicity (78), renal disease and reduced bone density (79). Development 
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of modern drugs has decreased the prevalence of adverse effects, and screening for known 
risk factors, such as human leukocyte antigen (HLA) B*57 which is correlated to abacavir 
hypersensitivity (80, 81), can help to prevent them. However, ART toxicity is still a 
considerable contributor to comorbidities in PLHIV, especially as survival increases (82, 83). 
A small group of PLHIV who start ART can experience immune reconstitution inflammatory 
syndrome (IRIS). Recovery of CD4 T cells upon initiation allows immune responses that 
were previously suppressed by HIV to rise (84). Thus, IRIS is more common in PLHIV with 
lower CD4 T cell counts prior to ART initiation (85, 86) and rapid recovery (85, 87). A 
possible explanation for IRIS is a difference in recovery rates between CD4 T cell subsets. A 
delay in regulatory T cell recovery in comparison to other subsets might leave immune 
responses unchecked until this delay is overcome (84). Prevention of IRIS is possible by 
screening PLHIV for opportunistic infections that are typically associated with IRIS, such as 
tuberculosis, other mycobacterial infections, Cryptococcus or viral infections. However, 
delaying ART initiation in order to avoid IRIS risks HIV disease progression. Furthermore, 
antigen associated with IRIS is not necessarily derived from active infections, but can also 
come from tumors, dead pathogens from resolved infections or even self-antigen, causing 
autoimmune symptoms (84).  
1.2.4 Acquired immunodeficiency syndrome 
Untreated HIV infection results in AIDS, when the immune deterioration renders host 
defense insufficient to maintain health. CD4 T cells are essential in orchestrating immune 
responses, development of B cell responses, maintenance of CD8 T cell memory, and 
functions of innate immune cells e.g. phagocytosis by macrophages. Through the lack of CD4 
T cells, these other immune cell types cannot maintain or execute their functions. Latent 
infections, such as cytomegalovirus (CMV), tuberculosis or herpes viruses, are no longer 
contained and can now cause death of severely immunocompromised patients. Typical 
AIDS-related malignancies are Kaposi´s sarcoma and B cell lymphomas, which are 
themselves caused by viral infections that are no longer contained, such as human herpesvirus 
8 and Epstein-Barr virus (EBV) (88). However, malignancies can also be the result of 
cytokine dysregulation (89). In addition to these AIDS-related conditions, a CD4 T cell count 
below 200 cells/mm3 is a criterion for AIDS diagnosis. As with other infections, the partial 
containment of HIV seen in the chronic phase ends and viral replication increases again. 
1.2.5 Pediatric disease progression 
MTCT can occur late in pregnancy, at birth or during breastfeeding. The transmission risk 
from untreated mothers to children varies from 15 to 35% (90) and depends heavily on 
disease severity of the mother and the frequency of breastfeeding. Other factors that influence 
the risk of transmission are related to the immune system or of genetic nature. Similarities in 
HLA alleles between mother and child play a role (91), especially if the alleles are associated 
with rapid progression (92). Some children of HIV infected mothers that were not infected 
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produced higher amounts of chemokines that bind to CCR5 (93), potentially competing with 
HIV for binding to the co-receptor. 
Disease progression in untreated HIV infected children is accelerated in comparison to 
infection of adults (94) with a median survival of only two years for vertically infected 
children compared to 11 years for PLHIV who acquired HIV later in life (95). It is speculated 
that this relates to the immaturity of the immune system at time of infection. However, the 
mode of transmission also influences progression, as children infected via blood transfusion 
experience slower disease progression compared to vertically infected children (96). This 
difference is in part caused by the similarities in HLA alleles, as the virus transmitted to the 
child is already adapted to the HLA alleles that are shared between the individuals (97).  
Compared to HIV infection in adults, viral replication in pediatric HIV infection is much 
higher at peak level and declines slowly until the set point is reached at approximately 5 years 
of age (98). CD4 T cell levels are generally higher in children due to the development of the 
immune system, which might fuel the elevated replication as target cells are more abundant. 
However, T cell depletion in HIV infected children is progressive over the duration of 
infection instead of halting at a plateau as seen in chronic infection of adults (99). 
Global efforts in diagnosing and treating pregnant women have reduced the number of 
vertical HIV infections and early initiation of ART for infected children has greatly improved 
survival. Screening of pregnant women has virtually eliminated MTCT in developed 
countries, essentially limiting vertical HIV infection to lower income countries, especially 
those with high incidence of HIV outside of risk groups. The problems regarding access to 
HIV testing and ART in those countries mean that diagnosis and treatment initiation of 
children is often delayed. In addition, regions where MTCT occurs are often struggling with 
other problems such as political conflicts, malnutrition, high infectious burden, but also 
stigma and discrimination of PLHIV. However, even in developed countries, pediatric HIV 
patients are at increased risk for virological treatment failure due to drug resistance (100), 
immunological failure or lower recovery of CD4 T cell count (101) and impaired vaccine 
responses (102).  
Non-AIDS illnesses such as problems with vertical growth, muscle strength, neurological 
development, metabolic, and cardiac health affect physical development at a critical age and 
can thus lead to permanent disabilities (83). Comorbidities are mostly related to immune 
activation, which is in turn caused by simmering HIV replication below detection limits 
despite ART. Treatment thus decelerates comorbidities but does not restore health to levels 
seen in HIV negative individuals. Consequently, older age at ART initiation exacerbates both 
pathogenesis and comorbidities. Conflicting results on differences in immune recovery 
depending on treatment regimen led to guidelines that discourage treatment changes in case 
of suboptimal immunological outcome despite viral suppression. Furthermore, studies of new 
types of ART in children and adolescents is often delayed (103). The potential of early ART 
initiation is considered highly advantageous and even speculated to harbor the potential for 
cure (104), if optimal conditions are met. In search for curative therapies, factors such as 
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residual viral replication and the resulting immune activation, as well as the size of the viral 
reservoir are considered critical and should thus be investigated in pediatric infection. Studies 
have shown a reduced size of the viral reservoir in infected children on continuous ART 
(105), highlighting the potential of ART optimization in vertical HIV infection.  
1.2.6 HIV-2 infection 
HIV-2 infection differs substantially from the HIV-1 pandemic. On a nucleotide level, the 
viral genome of HIV-2 displays 55% sequence similarity with HIV-1, resulting in 55% 
similarity on protein level for Gag and Pol, and 35% for Env (106). HIV-1 and HIV-2 share 
transmission routes and cellular tropism, however cytopathogenicity and replication capacity 
might differ (107, 108) and transmission rates are lower in HIV-2 (109). Some differences 
between HIV-1 and HIV-2 infection are related to the viral genome, like sensitivity to 
tripartite motif containing protein 5 α (TRIM5α) (110), escape from inhibition of reverse 
transcription (111, 112), downregulation of the T cell receptor (TCR) complex by Nef (113), 
or responsiveness to human transcription factors (114).  
In addition to host-virus interactions, the differences on genome and protein level have 
implications for diagnosis, monitoring and treatment (115). Diagnostic screening methods 
differ in their capability to detect HIV-2 due to variations in cross-reactivity between HIV-1 
and HIV-2 depending on the technique and components used. Furthermore, quantification of 
HIV-2 VL is complicated by both the limited availability of detection kits and high frequency 
of natural control, suppressing plasma VL below detection limits. Similarly, ART is 
optimized for HIV-1 and HIV-2 infection is associated with problems like slow recovery of 
CD4 T cell counts and high prevalence of ART resistance, both before treatment initiation 
and in response to suboptimal ART. HIV-2 is inherently resistant to several classes of drugs 
(NNRTIs and the only fusion inhibitor available), and treatment with other drugs (several 
protease inhibitors) is less effective compared to HIV-1 infection. Furthermore, testing for 
additional resistance mutations is complicated in patients without detectable VL. 
Consequently, undetected HIV-1/HIV-2 dual infection can contribute to immunological 
failure on ART, but due to the low prevalence of HIV-2 this is not frequently the case in 
regions other than Western Africa. 
Overall, HIV-2 infected individuals have lower viral set points and plasma VL compared to 
HIV-1 and the decline of CD4 T cells is slower (116-119). However, disease progression 
differs among HIV-2 infection, ranging from decade-long asymptomatic courses seen in a 
high proportion of viremic control (120, 121), to progression comparable to HIV-1 at similar 
VL and CD4 T cell counts (122, 123). Counterintuitively, AIDS onset in HIV-2 occurs at 
higher CD4 T cell levels when compared to HIV-1 (124, 125). 
Similar to progression, immune responses and activation differ among HIV-2 infected 
individuals. Lower pathogenicity of HIV-2 compared to HIV-1 prevails at high to moderate 
CD4 T cell counts and low VL, but diminishes when VL increases and CD4 T cell counts are 
increasingly affected (126). Natural killer (NK) cell cytotoxicity (127), microbial 
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translocation (128), T cell activation (129), and sensitivity to apoptosis (130) differ between 
aviremic and viremic HIV-2 infection and further highlight the importance to distinguish 
between these groups. Lower CD4 T cell activation in aviremic HIV-2 compared to viremic 
HIV-2, HIV-1 and HIV-1/HIV-2 dual infection also extends to differences in the quality of 
CD4 T cells. Programmed cell death 1 (PD-1) expression, a sign of exhaustion of T cells, 
remains lower in aviremic compared to viremic HIV-2 (131).  
In HIV-1 controllers, strong activation of both CD4 and CD8 T cells can suppress viral 
replication, but simultaneously contributes to depletion of CD4 T cells (132). The immune 
activation thus persists independent of viremia, and drives disease progression regardless. 
Similarly, aviremic HIV-2 infected individuals are not unscathed and still show pathogenic 
changes when compared to seronegative individuals and can progress to AIDS despite viral 
suppression (131). Interestingly, pre-existing HIV-2 infection even has the capacity to slow 
down HIV-1 disease progression in dual HIV-1/HIV-2 infection (133), which suggests that 
HIV-specific immune responses developed against HIV-2 can ameliorate HIV-1 already in 
acute infection before immune responses against HIV-1 can be mounted. 
1.3 HIV IMMUNOPATHOGENESIS 
The human immune system comprises two elements: components of the innate immune 
system recognize patterns that are common to pathogens, but not the human body, while cells 
of the adaptive immune system develop receptors that are unique to the specific antigen they 
are presented with. The development of the adaptive immune response requires genetic 
rearrangement based on coordinated antigen presentation and activating signals, a process 
that takes several days to reach potent efficacy. In contrast, the innate immune system relies 
on invariant receptors and cellular processes that can act immediately upon encounter of 
pathogens. 
The main purpose of the immune system is to ensure human health by eliminating pathogens, 
keeping the symbiotic microbiome in check and avoid damage to host tissue in the process. 
Thus, a delicate balance between effective defense and prevention of tissue damage are 
essential. HIV infection debilitates both, impaired defense against infection and tissue 
damage due to increased inflammation are part of the immunopathogenesis. 
1.3.1 Innate immune responses 
Epithelial surfaces, such as skin and mucosa, are often considered part of the innate immune 
system, as they represent a physical barrier that protects the host from the majority of 
invading pathogens. The most common first encounter with HIV happens at mucosal 
surfaces, genital and rectal mucosa. DCs patrol skin and mucosa with the purpose of taking 
up pathogens, process them and present them to cells of the adaptive immune system. HIV is 
bound by dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin 
(DC-SIGN) on the surface of DCs and taken up into vacuoles, where it can survive several 
days (21). In their pursuit to present the captured pathogen to immune cells, DCs migrate to 
draining lymphoid tissues, effectively presenting HIV with a high abundance of target cells. 
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DCs and other CD4 positive myeloid cell types are themselves rarely productively infected 
by HIV-1 due to SAM and HD domain containing deoxynucleoside triphosphate 
triphosphohydrolase 1 (SAMHD1) (111, 112). SAMHD1 inhibits HIV RT by restricting the 
access to deoxynucleoside triphosphates (dNTPs) required for DNA synthesis (134), thus 
preventing productive HIV infection. In contrast to HIV-1, HIV-2 possesses an accessory 
protein, viral protein x (Vpx), that interferes with SAMHD-1 mediated inhibition of HIV RT. 
SAMHD1, apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3 
(APOBEC3), TRIM5α, and tetherin are considered HIV-1 restriction factors. APOBEC3 is a 
cytidine deaminase, converting cytidine in viral RNA and DNA to uridine. This manipulation 
with the genome renders the virus incompetent. TRIM5α blocks HIV replication shortly after 
entering the cell by binding to the capsid protein. After budding of new HIV virions, tetherin 
retains the viral particle at the cell surface, preventing release of HIV virions from the 
infected cell. While these restriction factors restrain HIV infection, the virus counteracts 
restriction factors with the accessory proteins Vif, Nef, Vpu, and Vpr (135), enabling 
infection of myeloid cells (136). 
In cells exposed to viral RNA and DNA, the viral components are bound by receptors of the 
innate immune system, primarily toll-like receptors (TLRs) and retinoic acid-inducible gene-I 
(RIG-I) like receptors. This interaction between pathogen associated molecular patterns 
(PAMPs) with pathogen recognition receptors (PRRs) is essential to sensing of viral 
infections. The ensuing signaling cascades stimulate expression of cytokines and chemokines 
to attract, activate and differentiate surrounding cells, thus initiating the immune response to 
HIV. As part of this response, interferon is released from the infected cell and induces 
expression of interferon stimulated genes (ISGs), including PRRs themselves, thus 
intensifying local inflammation (137). In a similar fashion, HIV-induced inflammation is 
exacerbated by co-infections and microbial translocation. Sensing of PAMPs from bacterial 
and viral sources adds to the signals originating from HIV infection, increasing inflammation 
and risk for comorbidities. As a result of microbial translocation, LPS in circulation is 
captured by CD14 on the surface of monocytes and macrophages, which are in turn activated 
via TLR 4. Soluble CD14 (sCD14) is thus a marker of monocyte activation (138) and an 
indirect marker of microbial translocation (139). Monocytes and macrophages respond by 
production of inflammatory cytokines and coagulation factors (140-142).  
Successful recognition of PAMPs can abrogate HIV infection, but triggers pyroptosis in the 
course (143). The released cytokines attract and activate immune cells, and cytoplasmic 
contents serve as danger associated molecular patterns (DAMPs), which are additional 
triggers of innate immune responses and inflammation. Thus, pyroptosis is not only a major 
contributor to the depletion of CD4 T cells, but also the increased immune activation and 
inflammation seen in HIV pathogenesis (51). 
The main PAMPs of HIV are the DNA and DNA:RNA products synthesized by HIV RT. 
Thus, RT inhibitors included in ART regimen can reduce inflammation from innate immune 
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responses (137, 144). Given the persistence of HIV, ensuring RT inhibitors to permeate into 
anatomical sites of residual replication could improve immune recovery and comorbidity 
burden in ART treated PLHIV. 
NK cells are cytotoxic cells of the innate immune system that recognize tumor and infected 
cells. Their activation is mediated by interleukins, activated monocytes and macrophages, and 
their function is controlled by the net outcome of activating and inhibiting surface receptors. 
Killer immunoglobulin-like receptors (KIRs) on NK cells interact with HLA-C molecules, 
which drives their development and proliferation. High surface expression of HLA-C in 
PLHIV is associated with slower disease progression (145) and HIV develops mutations to 
escape from NK mediated immune responses (146), providing evidence for efficacy of 
immune response by NK cells. As cytotoxic cells, NK cells primarily combat HIV by 
inducing cell death of infected cells, but also shape the immune response by production of 
cytokines and chemokines (147).  
Tissue-resident macrophages, which are differentiated from circulating monocytes, play an 
important role in tissue homeostasis. Their main function is phagocytosis of pathogens, 
apoptotic or stressed cells. Depending on the context, they can act either pro- or anti-
inflammatory. In HIV, they are the second group of target cells in addition to CD4 T cells and 
might be part of the viral reservoir (148). When phagocytosing infected cells, they depend on 
signals like interferon-γ (IFNγ) and ligands on the CD4 T cell surface (21). When this CD4 T 
cell help is compromised, they can ingest, but no longer kill intracellular pathogens, which 
leads to the high prevalence of mycobacterial infections seen in AIDS. 
In addition to their roles in containing infection directly, cells of the innate immune system 
are important in modulation and activation of the adaptive immune system. They process 
antigen and present it to B and T cells together with co-stimulatory signals and thus initiate 
development of antigen-specific receptors. Stimulation of the adaptive immune response 
improves after activation and maturation/licensing of innate antigen presenting cells (APCs) 
by optimizing the expression of co-stimulatory signals. In HIV, the persistence of 
inflammatory signals past the acute phase of infection promotes inhibitory mechanisms in an 
attempt to avoid excessive tissue damage. One prominent example is PD-1 (CD279) with the 
ligands PD-1 ligand 1 (PD-L1, CD274) and PD-L2 (CD273). In HIV infection, upregulation 
of PD-L1 was detected on cells of the innate immune system and even on the surface of HIV 
virions (149). Expression of the receptor PD-1 is increased in HIV infection both on NK cells 
and T cells (150, 151), rendering these cells receptive to inhibition by PD-L1 expressing cells 
and impairing the crosstalk between innate and adaptive immune system.  
1.3.2 Cytokines and chemokines 
The crosstalk between cells of the immune system is mediated by soluble and membrane 
bound proteins. Receptor-ligand interactions coordinate recruitment, activation and regulation 
of cells, and can determine which components of the immune system contribute to the 
response at hand. While acute viral infections lead to controlled cytokine and chemokine 
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(chemotactic cytokine) responses, limited both in their anatomical and temporal distribution, 
HIV causes a systemic and permanent increase in inflammatory signals (152, 153). This 
sustained dysregulated response contributes to the immunopathogenesis of HIV infection. 
In an attempt to identify mechanisms of HIV protection or susceptibility, genome-wide 
association studies (GWAS) have advanced our knowledge in several aspects. The strongest 
protection found in these studies was a mutation of CCR5, CCR5Δ32, that results in a protein 
that R5-tropic HIV cannot bind to. People homozygous for this mutation are protect from 
HIV as it prevents viral entry and thus infection of target cells. PLHIV with heterozygous 
CCR5Δ32 experience partial protection as it is associated with slower disease progression.  
CCR5 is a chemokine receptor with three ligands, C-C motif chemokine ligand 3 (CCL3), 
CCL4 and CCL5, also known as macrophage inflammatory protein-1α (MIP-1α), MIP-1β 
and regulated upon activation, normal T cell expressed and secreted (RANTES). By binding 
to CCR5 these chemokines can suppress HIV in vitro (154). Furthermore, they are elevated in 
people who are HIV negative despite exposure (155, 156), and both MIP-1α and MIP-1β 
have been associated with suppression of viral load (157). MIP-1β takes part in 
polyfunctional CD8 T cell responses against HIV (158). However, their roles in competing 
with HIV for entry on one hand and as inflammatory mediators on the other hand do create 
conflicting results, especially with the introduction of treatment. As chemoattractants, C-C 
chemokines increase inflammation by activating endothelial cells and recruiting immune cells 
such as lymphocytes, monocytes and DCs. MIP-1α is produced by a number of cells, 
especially stimulated immune cells. Innate immune cells such as monocytes and neutrophils 
produce both MIP-1α and MIP-1β upon encounter of LPS, other PAMPs and cytokines. 
Furthermore, HIV infected macrophages and CD4 T cells can secrete MIP-1α (159). In ART 
treated HIV, MIP-1β was linked to problems with immune recovery (160) and MIP-1α 
correlates with problems of lipid metabolism (161).  
Interleukin-2 (IL-2) is a cytokine impacting a large number of hematopoietic cells. It induces 
proliferation of T cells, cell growth and survival. The potency of IL-2 mediated effects on 
CD4 T cells was investigated in clinical trials administering IL-2 to successfully treated 
PLHIV, which improved CD4 T cell counts. However, the resulting CD4 T cell activation 
also increased viral load (162) and IL-2 did not ameliorate clinical symptoms, possibly due to 
skewing features of CD4 T cells (163, 164). 
Tumor necrosis factor α (TNFα), mainly secreted from activated macrophages and T cells, 
activates several innate immune mechanisms and is associated with numerous inflammatory 
conditions. Depending on the cell type receiving TNFα signals, it can downregulate CD4 and 
CCR5 and simultaneously upregulate MIP-1α, MIP-1β and RANTES as well as HIV 
restriction factors. However, intracellular signaling activates transcription and thus viral 
mRNA synthesis in infected cells. Furthermore, it has been implicated in apoptosis of CD8 T 
cells. TNFα signaling has thus a multitude of outcomes, that strongly depend on the cell 
types involved (165).  
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Another member of the TNF superfamily, TNF-related apoptosis-inducing ligand (TRAIL), 
is expressed by NK cells, T cells and DCs. In the context of HIV infection, it was associated 
with contribution to CD4 T cell death (166). TRAIL and other ligands of the TNF 
superfamily bind to so-called “death receptors” and induce apoptosis via effector caspases 
(167), or necroptosis in case of infections that inhibit apoptotic pathways (168). Necroptosis 
is another type of inflammatory cell death very similar to pyroptosis, but rather than a direct 
effect of PAMPs and stress signals, it results from abrogated apoptosis (169). The increase of 
TRAIL in HIV is ameliorated upon successful ART and in vitro experiments showed that 
cells from PLHIV are more sensitive to TRAIL mediated apoptosis than those from 
uninfected people (170). 
IFNγ is produced in high levels by activated T and NK cells. It directly activates innate 
immune cells and influences CD4 T cell differentiation and indirectly enhances T cell 
responses by elevating peptide presentation. IFNγ levels in plasma of PLHIV is elevated and 
the cytokine contributes to HIV mediated inflammation. There are contrasting results 
regarding the influence of IFNγ on HIV disease progression, but it is often used as a marker 
for responses when evaluating HIV-specific immune responses in PLHIV or vaccine efficacy 
(171). 
The majority of pro-inflammatory cytokines and chemokines are beneficial in acute HIV 
infection, but the sustained and dysregulated nature of immune responses in chronic infection 
causes HIV immunopathogenesis. The increased survival of PLHIV on ART uncovers 
resulting problems, such as immunosenescence and comorbidities. 
1.3.3 Adaptive immune responses 
The adaptive immune system encompasses B cells, CD8 T cells, the main target cells of HIV, 
CD4 T cells, as well as rare T cell populations such as NKT cells or γδT cells. CD8 T cells 
are the focus of this thesis and will be discussed in more detail in the following chapter (see 
1.4 CD8 T cell responses). 
B cells are responsible for antibody responses and depend on CD4 T cell help within 
lymphoid follicles in order to develop an appropriate antibody isotype and optimize affinity 
for their cognate antigen. B cells themselves are not infected with HIV, but bystander effects 
decrease serological memory in HIV (172, 173). However, B cells can bind virions through 
receptors like CD21, DC-SIGN and C-type lectin receptors. In addition, indirect effects via 
infected macrophages and most strikingly the lack of CD4 T cell help affect B cells. HIV 
mediated immunopathogenesis leads to both activation and exhaustion of B cells, resulting in 
reduction of resting B cells and increases in activated and transitional memory subsets. 
Transitional B cells are weakly responsive to antigen stimulation and more sensitive to 
apoptotic signals like CD95. Exhaustion of B cells results in lower epitope diversity and 
proliferative capacity as well as senescence. HIV mediated B cell pathogenesis thus results in 
increased turnover and malignancies of B cells, and hypergammaglobulinemia with 
simultaneous loss of serological memory to vaccines (173).  
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CD4 T cells, also called helper T cells, are central to coordinating and shaping the appropriate 
immune response by providing support to other immune cell types. They recognize peptides 
that are processed and presented by HLA class II molecules on professional APCs. These 
cells are themselves immune cells and receive help in the form of membrane bound ligands 
and secreted cytokines by activated CD4 T cells. This crosstalk ensures optimal effector 
function, like phagocytosis by macrophages and maturation of DCs, as well as differentiation 
and optimization of adaptive responses, like class-switch of B cells and maintenance of CD8 
T cell memory. CD4 T cells differentiate into several subsets that balance the contribution of 
immune system compartments to the overall response by selectively boosting one cell type 
and suppressing others. Th17 cells are integral to homeostasis of the gut barrier function and 
regulatory T cells counteract tissue damage and maintain immune tolerance to signals like 
self-antigen or the symbiotic microbiome. In addition to depletion of regulatory CD4 T cells 
(174), which diminishes suppression of inflammation, the dysregulated cytokine environment 
also interferes with development of regulatory T cells (175). Both these subsets are strongly 
affected by HIV mediated CD4 T cell depletion and their loss contributes to HIV 
immunopathogenesis. 
HIV requires the cellular transcription machinery for viral mRNA synthesis. Transcription 
factors like nuclear factor κB (NFκB) and nuclear factor of activated T cells (NFAT) are only 
upregulated upon activation, and their absence in resting CD4 T cells results in latent 
infection. However, the highly inflammatory environment created by HIV causes excessive 
CD4 T cell activation and thus viral replication and cytopathic depletion.  
B cells receive CD4 T cell help by T follicular helper cells (TFH) in lymph nodes and this 
interaction depends on fibroblast reticular cells. In their attempt to curb the ongoing 
inflammation, regulatory T cells release transforming growth factor β (TGFβ), which results 
in fibrosis of lymph nodes. Fibrosis, the deposition of collagen, however replaces the 
fibroblast reticular cells and thus disrupts interactions between B cells and TFH (153). The 
subsequently dysregulated B cells are an additional source for TGFβ and create a vicious 
cycle culminating in destruction of the lymph node architecture (176). Furthermore, TFH were 
linked to persistent viral replication despite treatment (66) and are a proposed component of 
the viral reservoir. 
CD4 T cells also mount HIV-specific responses. Furthermore, elevated C-C chemokine levels 
produced by the HIV-specific CD4 T cell response were detected in individuals that were 
exposed to HIV, but remained uninfected (155) as well as long-term non-progressors (177). 
HIV infection stimulates proliferation of memory T cells and decreases the naïve pool of both 
CD4 and CD8 T cells. However, among CD4 T cells depletion dominates, while the CD8 T 
cell pool expands (178). The result is a skewed ratio of CD4 to CD8 T cells that reliably 
predicts disease progression and pathogenesis (179-181). 
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1.4 CD8 T CELL RESPONSES 
1.4.1 Successful T cell responses 
The majority of CD8 T cells in humans express αβ TCRs and are part of cytotoxic antigen-
specific responses. With their TCR, CD8 T cells recognize antigen presented in the form of a 
peptide/major histocompatibility complex (MHC) I molecule complex on the target cells. The 
epitope is a peptide, typically 9 – 11 amino acid long, bound to the peptide binding groove of 
HLA class I molecule, the human MHC I protein. This interaction between TCR and the 
peptide/HLA complex is the prerequisite for T cell activation, but it is not sufficient for full 
activation of CD8 T cells. Upon their first encounter with antigen, naïve CD8 T cells are 
typically presented with antigen in the context of other activating signals by DCs, which 
results in priming of the CD8 T cell. Naïve CD8 T cells express ligands such as CD28, which 
binds to CD80 or CD86 on APCs. This combination of TCR and co-stimulatory signals leads 
to priming or, in the case of differentiated T cells, execution of their respective functions. In 
the case of naïve T cells, priming results in strong proliferation and thus generation of both 
effector and memory T cells. 
Effector CD8 T cells are guided by chemokines to migrate to the infected or malignant tissue 
and carry out the primary response. Antigen recognition at the site of infection does not 
require the same extent of co-stimulation that induced priming (21, 182). Upon binding to a 
cell presenting the cognate antigen, effector CD8 T cells form an immunological synapse 
with the infected target cell. The resulting polarization transports cytotoxic granules towards 
this contact, where their contents are released in a targeted fashion. Perforin penetrates the 
cell membrane of the infected cell, enabling granzymes to enter the cell and trigger apoptosis 
(21). In addition, antigen recognition initiates de novo expression and secretion of cytokines 
such as IL-2, TNFα and IFNγ. The simultaneous expression of various effector molecules is 
termed polyfunctionality and an important aspect of successful CD8 T cell responses. 
Effector CD8 T cells are short-lived, resulting in contraction of the immune response after an 
infection is resolved.  
Memory T cells are a small subset of the primary response that provides long-term protection 
from previously encountered pathogens (183), but their survival is dependent on CD4 T cell 
help (184). Distinct subsets of memory T cells are associated with different functions, homing 
and thus expression of surface markers that are used for identification. In blood, memory T 
cells are usually characterized as central, effector or terminal effector memory T cells. 
Central memory T cells react to antigen exposure by proliferation, thus giving rise to immune 
responses upon second encounter with a pathogen. They still express the co-stimulator CD28 
and C-C chemokine receptor 7 (CCR7), which is associated with homing to lymph nodes. In 
contrast, effector memory T cells migrate to inflamed tissues and can rapidly execute effector 
functions. They have downregulated both CD28 and CCR7. Another marker used to 
distinguish T cell subsets is the phosphatase CD45. Naïve T cells express the isoform 
CD45RA, which then changes to CD45RO expression in central and effector memory T cells. 
However, terminal effector memory T cells express CD45RA and are also called TEMRA 
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cells, after their re-expression of CD45RA. With the use of more markers, additional subsets 
can be distinguished. For example, transitional memory T cells display an intermediate 
differentiation state between central and memory T cells. Transitional memory T cells have 
downregulated CCR7 but are still positive for CD28. Apart from circulating memory cells, 
tissue-resident memory T cells provide local immune responses and can be identified by the 
expression of tissue homing receptors. 
Surface protein expression changes in response to antigen encounter, which is often used to 
identify and quantify recently activated T cells. Some co-stimulators, such as CD226, OX40 
(CD134) or 4-1BB (CD137), are only upregulated as response to activation. However, 
changes in protein expression mediate a number of adaptations that distinguish resting from 
stimulated cells. CD38 is an enzyme with roles in cell adhesion, signal transduction and 
calcium signaling, and HLA-DR is an MHC class II molecule that mediates interaction with 
CD4 T cells. Antigen encounter results in proliferation of T cell subsets why proteins with 
roles in the cell cycle, such as Ki67 (185), but not expressed in resting cells, are typically 
used to quantify proliferation in response to T cell activation. CD69 is rapidly expressed upon 
stimulation but downregulated shortly after. Thus, CD69 is often used as an activation 
marker, but the physiological role is less clear. It has been suggested, that CD69 might 
restrain inflammation (186).  
In order to avoid tissue damage, autoimmune disorders as well as vascular damage, and 
resolve immune responses after acute infections, T cells also express co-inhibitory receptors 
(also called immune checkpoints) (187). Many of these inhibitory receptors share the same 
ligand with co-stimulators, resulting in direct competition. In an appropriate T cell response, 
co-inhibitors are thus upregulated as a direct result of T cell activation and often serve as 
activation markers in T cell biology. As pathogen is cleared and antigen exposure ends, 
effector T cells die by neglect, as they do not receive survival signals any longer. The 
remaining memory T cells decrease the expression of proteins associated with activation, 
including co-inhibitory receptors. 
The first activation of CD8 T cells is seen even before peak viremia and both rapid and 
abundant CD8 T cell responses are associated with a lower viral set point in chronic infection 
(188). This has implications for the clinical outcome, as peak viremia and the viral set point 
are linked to disease progression. Furthermore, the need for HIV to escape CD8 T cell 
responses visible by mutations in viral epitopes documents efficacy of the HIV-specific 
response (189, 190). However, the initial response of HIV-specific CD8 T cells does not 
succeed in clearing all virus-infected cells and thus viral replication remains after acute 
infection. 
Despite the connection of polyfunctionality and cytotoxicity of circulating CD8 T cells to 
better disease outcome in HIV, new studies have revealed that this is not the case in tissue. 
Non-cytolytic CD8 T cell responses in lymph nodes and other tissues (191) are beneficial for 
HIV-specific immune responses and highlight the importance of anatomical location and 
adaptation of the cells to their surroundings (192). 
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1.4.2 T cell exhaustion 
Persistence of antigen stimulation in chronic infections and cancer lead to T cell exhaustion. 
First studied in a murine model, the loss of IFNγ and reduced magnitude of a virus-specific 
response in chronic infection were noted (193). In addition to viral persistence, loss of CD4 T 
cell help exacerbates T cell exhaustion (194). The continuous antigen exposure maintains and 
increases expression of inhibitory receptors and drives progressive loss of proliferative 
capacity and polyfunctionality, as well as changes in the transcription factor profile, 
epigenetic landscape and metabolism of the affected T cells (195-198). Even though antigen 
exposure is the main driver of T cell exhaustion (199), viral suppression with ART can only 
slow down, but not completely halt upregulation of inhibitory receptors, which is probably 
related to the residual replication. 
PD-1 was among the first inhibitory receptors described in exhaustion and more specifically 
in HIV (200-202). Subsequent studies implicated several other inhibitory receptors, such as 
cytotoxic T-lymphocyte associated protein-4 (CTLA-4), killer cell lectin like receptor G1 
(KLRG1), CD160 and CD244 (2B4) both in cancer and HIV (203). The upregulation of 
inhibitory receptors can progress in two aspects, increasing the expression level of any given 
inhibitory receptor, and the accumulation of multiple receptors per cell. The expression level 
can determine whether exhaustion is reversible, as is the case for cells with low, but not high 
levels of PD-1 (204, 205) and receptors can synergize in their inhibitory function, as 
demonstrated for T cell immunoreceptor with Ig and ITIM domains (TIGIT) and PD-1 (Fig. 
2) (206, 207). Apart from their expression on T cells, the impact of inhibitory receptors is 
also determined by the expression of their ligands on surrounding cells, as mentioned for the 
ligands of PD-1 on innate immune cells (1.3.1. Innate immune responses). 
In addition to the synergy with PD-1, TIGIT counteracts co-stimulation mediated by CD226 
(208), which is required for T cell activation by non-professional APCs (209). TIGIT and 
CD226 share a ligand, poliovirus receptor (PVR, CD155), for which TIGIT has a higher 
affinity than CD226 (Fig. 2). Furthermore, TIGIT disrupts dimerization of CD226 (206), 
which is necessary for co-stimulatory signaling. In chronically HIV infected individuals, 
TIGIT expression is increased (210) and expression of CD226 is decreased (211), suggesting 
that the TIGIT/CD226/PVR network contributes to exhaustion mediated by HIV. 
In contrast to TIGIT and PD-1, both of which possess immunoreceptor tyrosine-based 
inhibitory motifs (ITIMs), 2B4 possesses an immunoreceptor tyrosine-based switch motif 
(ITSM), which enables the receptor to take on either a co-stimulatory or an inhibitory role 
(212). Most insight into the functions of 2B4 stem from NK research, where it was shown 
that the expression level of 2B4 and the availability of both the ligand CD48 and adaptor 
molecules determine about the signaling outcome of 2B4 (212). In addition, 2B4 was shown 




Figure 2. Interactions between regulatory networks analyzed in this thesis.  
Another hallmark of T cell exhaustion is the gradual loss of polyfunctionality of antigen-
specific T cells. IL-2 is a potent cytokine in T cell responses against HIV (214, 215) and 
among the first effector molecules lost in exhaustion (195). IL2 promotes T cell homeostasis 
by induction of proliferation, which directly links it to the CD4 T cell count in PLHIV. In 
contrast, IFNγ expression and degranulation are features that are maintained until late stages 
of exhaustion. Especially degranulation of empty granules when expression of cytotoxic 
molecules has already been lost is associated with ineffective T cell responses in HIV (216). 
The transcription factors T-box transcription factor 21 (T-bet) and eomesodermin (Eomes) 
regulate effector function and memory survival of CD8 T cells (217). They seem somewhat 
mutually exclusive, as high expression of either is associated with intermediate levels of the 
other, giving rise to T-bethi/Eomesdim and T-betdim/Eomeshi transcription profiles. T cell 
exhaustion in HIV has been linked to a shift towards the T-betdim/Eomeshi profile (218). 
However, T cell exhaustion seems to be initiated early in the differentiation process and 
recent insights into the transcription factor and epigenetic landscape of T cells has linked a 
progenitor subset of exhausted T cells to the transcription factor thymocyte selection 
associated high mobility group box (TOX) (219).  
While many mechanisms and key players of T cell exhaustion are shared between CD4 and 
CD8 T cells, some differences remain. Based on development and differentiation, the 
functional markers for CD4 and CD8 T cells are inherently different. Furthermore, the 
specific inhibitory receptors that accumulate on the cell surface depend on the cell type, as 
well as environmental factors. CTLA-4, hepatitis A virus cellular receptor 2 (HAVCR2, 
better known as Tim-3) and lymphocyte activating 3 (Lag-3) are readily detectable on CD4 T 













1.4.3 Influence of HLA-alleles on T cells and HIV infection 
Some of the strongest and most consistent genes associated with protection in HIV GWAS 
studies are HLA class I genes, especially HLA-B*57:01 (220, 221). Their role in antigen 
presentation to CD8 T cells directly implicates CD8 T cell responses in this protection. In 
contrast, some other HLA genes are linked to susceptibility to and rapid progression of HIV 
infection, demonstrating the devastating effect of impaired HIV-specific CD8 T cell 
responses (222, 223). 
Proposed mechanisms for the influence of HLA genes include structural features of the 
peptide binding groove, which determines the peptide sequences that can be presented and 
thus the capability to present conserved sequences (e.g. from HIV-Gag p24). Mutations in the 
targeted conserved HIV region to escape the associated immune response dramatically 
diminish virulence or fitness of the virus and thus slow down disease progression (224). 
Certain HLA alleles might also promote the development of cross-reactive or high affinity 
TCRs (225), thus shaping the T cell repertoire. Furthermore, decreased sensitivity to 
regulatory T cell suppression by HLA-B*57 was demonstrated (226), causing stronger 
immune responses in general. This might be one factor in the association of HLA-B*57 
positive PLHIV with slower disease progression, autoimmune comorbidities and lower 
prevalence of hepatitis C virus (HCV) (227). 
In the context of HLA-B*57 in HIV infection, protection has also been linked to the specific 
epitopes targeted (228, 229), high-magnitude HIV-specific responses early in infection (230), 
cross-reactivity (231), as well as the capability to target viral mutations with CD8 T cell 
responses that include IL-2 and perforin (232). 
However, the extent of protection conferred by HLA-B*57 is not equal among these 
individuals and comparing PLHIV with different progression rates (214, 233) implicate a 
complex interplay of virus and host interaction in this difference that is not fully understood 
yet. 
1.5 CURRENT CHALLENGES IN HIV RESEARCH 
1.5.1 Comorbidities 
For PLHIV accessing ART, especially when initiated timely, life expectancy is now close to 
that of the HIV negative population (234). However, comorbidities, or non-AIDS-defining 
illnesses, reduce quality of life despite viral suppression and are increasingly the cause of 
death among PLHIV (235, 236). Comorbidities include chronic lung disease, frailty 
syndrome, bone disease, neurological symptoms, immunologic ageing, renal impairment, 
dermatologic manifestations, cardiovascular and liver diseases as well as malignancies (83, 
237, 238). 
The main drivers for these complications are adverse effects of ART, co-infections and 
residual HIV replication causing immune activation and deterioration. However, factors like 
disease severity at ART initiation, older age, as well as life-style related risk factors such as 
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alcohol consumption and smoking, influence the development of comorbidities. Some of 
these risk factors and mechanisms are universal, while others differ between populations. 
Other infectious diseases and delayed ART initiation are more prevalent in low and lower-
middle income countries, while air pollution is often associated with urban settings. 
Malnutrition and CMV infection are important factors in pediatric HIV infection and 
exacerbate comorbidities that interfere with development (83).  
In the general public, the prevalence of metabolic syndrome increases due to modern life-
style changes (239). However, HIV infection and ART, especially early drugs, increase the 
risk of insulin resistance and abnormal lipid metabolism, even in children (240-243). 
Metabolic syndrome affects numerous organs, especially liver and kidneys, as well as fat 
distribution. In combination with immune activation, metabolic syndrome also causes 
endothelial dysfunction, atherosclerosis and hypertension, which in turn increase the risk for 
myocardial infarction and stroke (244), as well as neurological disorders like dementia (245).  
Overall, HIV-mediated immune dysregulation leads to increased pro-inflammatory signals 
and decrease of immunomodulatory, or anti-inflammatory processes. Cytokines, like IL-6 
and interferon-inducible protein 10 (IP-10, CXCL10), soluble biomarkers that result from 
monocyte and macrophage activation (246), components of the complement system and 
coagulation factors are elevated in plasma of PLHIV (247). Furthermore, oxidative stress and 
dysregulation of reactive oxygen species contribute to inflammation and tissue damage (248). 
Co-infections, especially other chronic viral infections such as CMV, HBV, HCV and EBV 
(249-251) also contribute to the chronic inflammation. As a result of immune activation and 
dysregulation, the immune system, especially the T cell compartment, of PLHIV shows signs 
of immunosenescence normally seen in advanced age (142), such as upregulation of the 
senescence marker CD57 (252) and shortened telomere length (253).  
Chronic inflammation results in tissue damage of numerous organs and interferes with their 
physiological functions. Reduced thymic function, a contributor to the loss of CD4 T cells, 
does not recover with initiation of ART (254). Disruption of the gut epithelium, resulting in 
microbial translocation (255), also strongly influence comorbidities. Common complications 
in PLHIV associated to microbial translocation and thus elevated sCD14 concentrations are 
cardiovascular disease (256) and inadequate CD4 T cell restoration on ART (257). 
Given the numerous mechanisms in which chronic inflammation contributes to development 
of comorbidities, evidence for cumulative effects of low grade replication despite ART on 
comorbidities, immune recovery, and disease progression (258, 259) is not surprising and 
stresses the importance of viral suppression. Vertically infected children are facing a life with 
the chronic infection, associated lifelong treatment and pathogenesis and cumulative exposure 
to HIV and ART immune activation (260). The higher viral load in vertically infected 
children increases T cell activation (261) and thus exhaustion (202) compared to adults. 
Together with disturbances of the B cell compartment, this decreases response to vaccinations 
(262, 263). Given the evidence that disease continues to progress despite treatment and 
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suppressed virus levels, these children are at much higher risk of several non-AIDS events, 
including atherosclerosis and metabolic syndrome, at a young age (264).  
HIV is not directly carcinogenic, but the immunosenescence/immunosuppression, co-
infection with oncogenic viruses and increased inflammation further contribute to the 
elevated risk of cancer in PLHIV (265, 266). Depending on their association with disease 
severity, malignancies are classified into AIDS-defining cancers and non-AIDS-defining 
cancers (251). While the risk for AIDS-defining cancers decreases with ART, non-AIDS 
defining cancers are more common due to increased survival of PLHIV. 
1.5.2 HIV cure research 
To end the HIV pandemic, research focusses on two approaches that complement one 
another: prevention of new infections by vaccination or other preventative methods as well as 
curative therapy. Currently, the increase in drug resistant HIV, requirement for life-long 
adherence and limitations in access to both diagnosis and treatment are major challenges in 
the fight against HIV and would greatly benefit from both vaccines and curative therapy. 
HIV vaccines, if effective, would hold an enormous promise in fighting the spread of HIV. 
Although antibodies against HIV Env develop in the vast majority of patients, the high 
mutation rate of HIV leads to rapid escape and viral evolution of the targeted protein. Most of 
the conserved parts of Env, and thus promising epitopes, are shielded by glycan residues and 
consequently inaccessible for antibodies. However, broadly neutralizing antibodies, targeting 
epitopes that are conserved not only across escape mutations of autologous viral variants but 
also across HIV-1 clades, have been isolated from patients. These antibodies typically require 
two to three years of infection to develop, as they are the result of extensive somatic 
hypermutation, show unusual characteristics (267), and target one of only six epitopes of HIV 
Env (268). However, both the potency and breadth of these antibodies vary and could be used 
in different ways. The most potent antibodies neutralizing the broadest range of HIV variants 
might not be a realistic target for vaccine strategies, but passive transfer for both prophylaxis 
and therapy showed encouraging results in animal models and early human trials (268). 
However, HIV rapidly develops resistance to administration of a single antibody, 
demonstrating the need for combination therapy as used with current ART drugs. 
In contrast to adult patients, vertically infected infants can develop broadly neutralizing 
antibodies as early as one year after infection (269). Development of these antibodies was 
associated to infection with at least two variants of HIV, highlighting the importance of 
exposure to diverse viral sequences. Reduced diversity of viral sequences in addition to the 
time needed for extensive somatic hypermutation might contribute to the long time required 
to develop broadly neutralizing antibodies in adults. However, infection with two HIV strains 
is still not sufficient to broaden antibody responses in adults the same way as in children 




Curative treatments have two potential outcomes: functional and sterilizing cure (270). The 
latter is defined as the complete elimination of pathogen from the host and might not be 
achievable for HIV due to the viral reservoir. A functional cure, or HIV remission, would 
entail long-term control of both viral replication and disease progression without the need for 
medication. Elite controllers might mimic functional cure, as they are control viral replication 
and maintain CD4 T cell count for years, but low grade replication and immune activation 
lead to comorbidities and prove that they are not unscathed either (271). So far, only two 
patients were cured from HIV infection. Both patients received stem cell transplants that 
replaced their immune system with hematopoietic cells harboring the homozygous CCR5Δ32 
mutation (272, 273). To circumvent the need for rare compatible donors with the 
homozygous mutation, in vitro gene editing of CCR5 using zink finger nuclease or short 
hairpin RNA was used to either introduce double-strand breaks in the gene, mimicking the 
CCR5Δ32 mutation, or downregulate CCR5 on stem cells. However, so far none of these 
approaches has led to durable results (274). In one clinical study, gene editing of CCR5 with 
clustered regularly interspaced short palindromic repeats (CRISPR) resulted in successful 
engraftment, but low frequency of the edited gene (275). Other approaches aim at using 
CRISPR to directly target HIV sequences in infected cells (276). 
As the longevity of the viral reservoir is the main challenge in preventing cure of HIV, 
several ways have been explored to either address or exploit it. The size of and mechanisms 
establishing the latent reservoir, as well as cell populations that contribute to either latent 
infection or viral rebound after treatment interruption are among the key questions in 
targeting viral persistence. Studies of ART intensification (addition of a fourth or even fifth 
drug to standard triple therapy) (277) or very early ART initiation (278) suggest that it is 
indeed possible to reduce, though not eliminate, the viral reservoir. Latency reversing agents 
(LRAs) are hypothesized to reactivate latent virus, allowing elimination by immune 
responses, ART or cytopathogenicity and thus “flush out” the reservoir (279). Thus far no 
single LRA has shown sufficient results at tolerable doses (280).  
A similar approach is the use of immune checkpoint inhibitors (281). These inhibitors have 
been successfully used in cancer immunotherapy to reverse T cell exhaustion and induce 
immune responses clearing tumor cells. Monoclonal antibodies against inhibitory receptors or 
their ligands disrupt interaction of the binding partners without triggering the inhibitory 
signal, consequently reinvigorating T cell responses (282). However, only a subset of cancer 
patients responds to checkpoint blockade and this response is associated with severe immune-
related adverse effects. Nevertheless, success in malignancies with poor prognosis has led to 
approval of monoclonal antibodies blocking interactions of PD-1 and CTLA-4 with their 
respective ligands, and further antibodies are in development (283). In regard to HIV, 
checkpoint blockade is hypothesized to aid a “shock and kill” concept (270, 280). 
Diminishing inhibition of CD4 T cells simultaneously facilitates T cell responses and 
reactivation of latently infected cells. Furthermore, direct effects on CD8 T cells expressing 
the same inhibitory receptors as well as indirect effects via CD4 T cell help should boost 
HIV-specific CD8 T cell responses and thus promote elimination of infected CD4 T cells. 
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Apart from T cells, NK cells also benefit from the improved CD4 T cell help (284). Ideally, 
checkpoint blockade would disrupt the pathogenic mechanisms of HIV infection and lead to a 
durable stalemate between virus and immune system, with minimal overall immune 
activation but highly effective responses targeted against HIV. A pioneering study used PD-
L1 blockade in PLHIV recruited patients with residual, but still detectable viral load below 
standard detection limit (285). In two of the six patients, HIV-specific CD8 T cells responded 
with production of IFNγ, TNF or degranulation. Response in only a fraction of treated 
individuals is reminiscent of cancer therapy and might reflect expression levels of PD-1 
(286). High expression levels of PD-1 render exhaustion irreversible, while lower expression 
levels allow for reinvigoration by checkpoint blockade. 
Contrary to reactivation, the “block and lock” approach is based on the concept of “deep 
latency” (287). Latency promoting agents are supposed to durably suppress HIV and prevent 
future viral rebound currently seen upon ART cessation. However, inactivation of CD4 T 
cells resulting from this approach might exacerbate immunosuppression of PLHIV. 
Another approach inspired by cancer immunotherapy is the generation of chimeric antigen 
receptor (CAR) T cells (288), which combine the antigen binding domain of antibodies with 
intracellular signaling domains of the TCR/CD3 complex. Further T cell based approaches 
aim at harnessing γδ T cells, non-cytolytic CD8 T cells or modulate T cell function with 





2 RESEARCH AIMS 
The overall aim of this thesis was to gain more insight into the immune deterioration seen in 
HIV infection, both on a systemic level caused by immune activation and inflammation, and 
on HIV-specific CD8 T cells as a direct consequence of the HIV-specific immune response. 
Paper I: The inhibitory receptor TIGIT had recently been described in cancer 
immunotherapy research. Our aim was to investigate the role of TIGIT during T cell 
exhaustion in HIV infection and it´s relation to the transcription factors T-bet and Eomes in 
PLHIV cohorts with different disease and treatment status. 
Paper II: Protective HLA alleles are associated with slower disease progression and effective 
HIV-specific CD8 T cell responses. We hypothesized that this association extends to less 
evident exhaustion of HIV-specific CD8 T cells restricted by the protective HLA allele in 
early untreated infection. To this end, we analyzed polyfunctionality, inhibitory receptors and 
transcription factors of responses restricted by HLA-B*57 or other HLA alleles. 
Paper III: Viral replication in HIV-2 infection is often controlled by the immune system. 
However, progression to AIDS in HIV-2 infection can occur despite controlled viremia. We 
set out to describe activation and exhaustion of CD8 T cells in HIV-2 infection with or 
without detectable levels of viremia. 
Paper IV: Perinatally infected children are a small proportion of PLHIV with higher risks for 
a number of comorbidities and complications than adult PLHIV. We set out to analyze 




3 MATERIALS AND METHODS 
3.1 PATIENT MATERIAL 
To describe details of TIGIT expression on circulating CD8 T cells and the influence of ART 
for paper I, blood samples from PLHIV under care in Swedish Hospitals (Karolinska 
University Hospital Huddinge and Stockholm South General Hospital) were drawn. These 
represent untreated PLHIV (n = 30) and PLHIV on long-term ART (n = 20, treatment > 6 
years, viral suppression > 5 years). Samples from acute infection (n = 12) and elite controllers 
(n = 14) were retrieved from the OPTIONS (290) and SCOPE (291) studies in the US (San 
Francisco General Hospital). Healthy control samples were recruited in Stockholm (n =26). 
HIV diagnosis as early as acute infection is rare. However, regular screening of risk groups in 
countries where the majority of HIV infections are associated with these populations enable 
studies of acute infection. Elite controllers represent outliers with regards to disease 
progression and while the exact number depends on the criteria used, they make up less than 
1% of PLHIV (292). As new infections with HIV decrease over the years, recruitment of 
such rare patient populations requires involvement of large cohort studies and programs. 
To evaluate PVR expression within lymph node resident cells, paired lymph node and blood 
samples from PLHIV and HIV negative control subjects were obtained from the National 
Institute of Respiratory Diseases, Mexico City, and the University of Pennsylvania, US, 
respectively. In contrast to peripheral blood samples, which are associated with very low risk, 
collection of lymph nodes poses a larger risk for the individuals. Biopsies without a medical 
reason, as in well treated PLHIV and healthy people, are hard to justify ethically, but medical 
reasons for lymph node biopsies are typically connected to diseases that interfere with the 
studies at hand. One such example is the removal of adjacent lymph node during cancer 
surgery. While there is a medical reason (determining whether malignant cells have 
metastasized), cancer does have a major influence on the immune system with an emphasis 
on T cell exhaustion, much like HIV. 
Paper II investigates the influence of the HLA-B*57 allele on CD8 T cell responses over the 
course of chronic infection. Peripheral blood mononuclear cells (PBMCs) from six HLA-
B*57 positive and six HLA-B*57 negative PLHIV from the OPTIONS (290) cohort were 
obtained. Healthy control samples were recruited in Stockholm, Sweden. 
The individuals involved in this study stayed mostly untreated (except for temporary 
treatment in two individuals). Since the introduction of triple combination ART (available in 
1996), recommended treatment initiation has been revised regularly with rising CD4 T cell 
count thresholds. Since 2015 the world health organization (WHO) recommends treatment 
for all PLHIV regardless CD4 T cell count. In the course of research studies, treatment 
conforming with standards of the time has to be offered and recommended to the study 
participants. Thus, studies of longitudinal untreated PLHIV is not possible beyond 2015. 
However, based on the regulations at the time of sample drawing, the participants in the 
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OPTIONS cohort had the choice to either start treatment at a CD4 T cell count of 350 
cells/mm3 or choose to initiate ART right at diagnosis. 
Comparison of groups of HIV-2 infected individuals in paper III was performed with blood 
samples drawn from an occupational cohort in Guinea-Bissau (293). In addition to the HIV 
negative control group (n = 27), PLHIV groups included HIV-1 infection, ART naïve or 
treated with virological failure (n = 12), successfully treated HIV-1 infection (n =8, VL < 75 
RNA copies/ml), HIV-2 infection (n = 23) and HIV-1/HIV-2 dual infection (n = 5). For more 
detailed analysis, HIV-2 infected PLHIV were divided into viremic (n = 9) and aviremic (n = 
14, VL < 135 RNA copies/ml). 
Given the large proportion of viral control and asymptomatic disease course of HIV-2 
infection, recruitment at medical health care facilities will underrepresent aviremic HIV-2 
infection. In addition, geographic and genetic factors greatly impact the immune system and 
need to be considered when recruiting HIV negative control groups. The frequency of 
exposures and nature of pathogens encountered in different parts of the world as well as 
alleles, polymorphisms and differences in copy numbers of genes shape the human immune 
system considerably. Thus, choices regarding the recruitment of control subjects can impact 
study results. Individuals of this cohort are recruited via their place of work and screened for 
infections in retrospect, avoiding bias towards symptomatic individuals among PLHIV. 
In paper IV, we evaluated immune activation in vertically HIV infected children (n = 20, 4 – 
14 years of age) and adolescents (n = 14, 16 – 20 years of age), as well as control groups of 
HIV negative children (n = 17, 2 -15 years of age) and horizontally HIV infected adults (n = 
51). Blood samples were collected at Karolinska University Hospital Huddinge. 
Studies involving individuals underage require heightened emphasis on information and 
consent. The informed consent in studies involving children is given by parents or guardians 
and the child when possible. In addition, the vast majority of pediatric HIV infections in 
Sweden are children who immigrated to Sweden after birth. Language problems and being 
unfamiliar with local regulations can be the source of misunderstandings that need to be 
avoided. Furthermore, recruitment of the control group comprising HIV negative children 
faces problems like matching age, ethnicity and/or country of origin, as well as extra blood 
vials not collected for treatment or monitoring purposes. To mitigate the addition of harm or 
risk, volume of medically indicated blood drawing was increased by the sample used in our 
study. For this reason, HIV negative subjects included children either with medical conditions 
other than HIV infection, such as agammaglobulinemia or conditions affecting iron 
metabolism, followed up after recovering from a disease, or siblings of PLHIV. Exclusion of 
infectious diseases or conditions with known impact on the immune system is crucial, but the 
recruited group still represents individuals differing from the age-matched general public with 
regards to their health status. 
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3.2 FLOW CYTOMETRY 
Multicolor flow cytometry is a single cell method widely used in cell biology, especially 
immunology. Cells are stained with fluorescent probes, most commonly antibodies coupled 
to fluorescent dyes, and analyzed for attached or internalized probes. The dyes are excited 
with the use of lasers and the emission of photons is detected after passing through filters to 
separate them by wavelength and photomultipliers to adjust the intensity of the signal to an 
appropriate range for quantification. Due to spectral overlap of the excitation and emission 
wavelengths, the number of parameters analyzed simultaneously is restricted by ways of 
distinguishing between the dyes. Separation of the signals is achieved by using multiple 
lasers and filters with defined wavelengths, minimizing overlap of excitation and emission 
spectra of the dyes in the experiment design and during subsequent analysis (compensation). 
Improvements of the involved components continue to increase the number of simultaneously 
detected parameters and thus dimensionality of the data. Analysis at single cell level is 
achieved by using cell suspensions at concentrations that allow cells to pass through a fluidics 
system one by one. 
3.2.1 Experimental designs 
Analysis of HIV-specific T cells in paper I and II was achieved by two different 
experimental designs. The main method used was stimulation with peptides, either a pool of 
peptides covering a defined region of viral genomes, or well described epitopes contained in 
the patient´s autologous viral sequences and presented by their HLA alleles. HIV-specific T 
cells were then identified by the means of antigen-specific responses like IFNγ expression, or 
extracellular localization of CD107a, a sign of degranulation. Furthermore, responses are 
defined as a minimum of 0.05% responsive cells after subtraction of the background signal in 
corresponding unstimulated samples, and at least twice the background signal. Alternatively, 
tetramers were used. These are protein complexes of four HLA molecules presenting defined 
epitopes and coupled to fluorescent dyes. Peptide stimulation limits the identification of T 
cell responses to cells expressing at least one of the functional markers, thus leaving out 
terminally exhausted cells, and might change expression of some markers by activating the 
cells. Use of peptide pools identifies a wider range of T cell responses by covering several 
epitopes included in the pool and processed and presented by the patient´s PBMCs. Epitopes 
represent a more narrow immune response and allowed to distinguish between responses 
restricted by either HLA-B*57 or other alleles. In contrast, use of tetramers is limited to the 
combinations of HLA alleles and viral sequences available either commercially or from 
collaborating laboratories, but has the benefit of identification of all specific T cells, including 
those incapable to express functional markers. 
Blood samples for CD8 T cell analysis in paper III were collected in Cyto-Chex BCT tubes 
(Streck) due to the limited infrastructure at hand in Guinea-Bissau. The blood collection tubes 
do contain preservatives that allow for sample integrity despite storage at room temperature 
for 14 days before processing (294). However, the preservation interferes with cell functions, 
thus peptide stimulation and functional analysis was not possible with these samples. 
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Markers used in flow cytometry included extracellular markers like the lineage markers CD3, 
CD4 and CD8 for basic identification of CD4 and CD8 T cells, differentiation markers, 
inhibitory and co-stimulatory receptors, as well as intracellular proteins like effector 
molecules and transcription factors, depending on the scientific question addressed in the 
paper. 
3.2.2 Data analysis and presentation 
Integration of the single cell analysis from flow cytometry, clinical information and 
comparison of multiple conditions per sample/patient (e.g. peptide stimulations) require 
advanced bioinformatics to handle the large multidimensional data sets. 
Raw data from flow cytometry were processed and either exported from or analyzed with 
current versions of FlowJo (Treestar). For clustering methods, uncompensated data are used, 
but in order to focus our analysis and decrease the size of the data set, we first gated on live T 
cells and exported this smaller data set for further use. Determination of cell population 
frequencies and combining expression data after Boolean gating were achieved in FlowJo. 
Combinations of simultaneously expressed markers, such as the variety of upregulated 
inhibitory receptors on a given cell or the polyfunctionality in response to peptide stimulation, 
were analyzed and visualized with Simplified Presentation of Incredibly Complex 
Evaluations (SPICE) (295). By combining pie charts and box plots, this user-friendly method 
allows comprehensive presentation. However, expression of markers is only evaluated to the 
extent of a cell being positive or negative for any given marker, which does not fully capture 




Figure 3. Automated clustering and visualization tools viSNE and FlowSOM. Adapted 
from paper I and paper III. 
Problems like compensation artefacts (the correction for spectral overlap of fluorescent dyes), 
scarcity of some cell populations, gradual expression of markers or subjectivity of manual 
gating can be addressed better by using unsupervised clustering methods (296). Both, viSNE 
(297) (Fig. 3A) and FlowSOM (298) (Fig. 3B) are visualization tools based on clustering 
algorithms. They aim to preserve information of the high dimensional data but represent them 
in two-dimensional plots. ViSNE visualizes cells similar to a scatter plot and can be colored 
by predetermined cell populations or according to the expression gradient of a single marker. 
FlowSOM uses self-organizing maps (SOMs) clustering for analysis and a combination of 































For analysis of plasma biomarkers for paper III, we used Bio-Plex Multiplex (Bio-Rad) and 
ProcartaPlex (Thermo Fisher) immunoassays. The approach is similar to flow cytometry in 
the use of fluorescent probes to identify and quantify different markers. However, instead of 
attaching probes to cells, magnetic beads are used to capture and quantify biomarkers such as 
cytokines and chemokines. The magnetic beads are identified by the ratio of two fluorescent 
dies, creating a two-dimensional matrix of up to 100 distinct beads and thus biomarkers. 
Antibodies coupled to the surface of these beads capture the biomarker from plasma samples. 
Subsequently, a second antibody with biotin attached to it is added to the complex. In a last 
step, the third fluorescent dye is bound to the complex. This third dye allows quantification of 
the biomarker. 
Depending on commercial availability and flexibility, a high number of biomarkers can be 
simultaneously quantified within a sample, thus minimizing the volume of sample required 
for analysis. As this project involved blood samples from children, this was particularly 
helpful. Especially from young children, the volume of available sample can be very low and 
analyzing a multitude of markers from small sample volumes ensures maximal use from 
these precious specimens. 
3.4 STATISTICAL ANALYSIS 
For statistical evaluation of our data sets, we used GraphPad Prism, Stata, R environment and 
SPICE software. For analysis in SPICE, viSNE and FlowSOM, the integrated statistical tests 
were used (e.g. permutation test and Student´s t test in SPICE). Frequencies of clusters from 
FlowSOM were also exported and subsequently analyzed in GraphPad Prism. 
For comparison of two groups, we used Mann-Whitney U test for unmatched samples and 
Wilcoxon-matched pairs signed rank test for matched samples (e.g. before and after initiation 
of ART). Comparisons of multiple groups were done with one-way ANOVA and subsequent 
Kruskal-Wallis non-parametric Dunn´s multiple comparisons test. Correlations were 
determined with Spearman rank test for the most part. However, analysis of some 






4 RESULTS & DISCUSSION 
Systemic immune deterioration and CD8 T cell exhaustion are a prominent feature of HIV 
infection. Viral and host genetic, host immununological factors, as well as medical 
interventions influence this process. Here, we analyze markers of immune deterioration with 
a focus on CD8 T cell exhaustion in treated and untreated HIV-1 infection (paper I), the 
influence of partial protection mediated by HLA-B*57 (paper II), aviremic compared to 
viremic HIV-2 infection (paper III) as well as the role of vertical HIV-1 infection and age in 
children and adolescents (paper IV).  
4.1 HIV-1-SPECIFIC CD8 T CELL RESPONSES 
Persistent antigen exposure is the main driver of T cell exhaustion, thus HIV-specific CD8 T 
cell responses are affected by immune deterioration to a larger degree than other CD8 T cell 
populations. However, in their role as antigen-specific T cytotoxic cells in limiting viral 
persistence, and spread, they might also hold the largest potential for therapeutic intervention. 
4.1.1 TIGIT is linked to HIV-1 mediated T cell exhaustion 
In paper I several groups of PLHIV were studied, including treatment naïve and ART treated 
individuals experiencing chronic infection, PLHIV during acute infection, as well as elite 
controllers. To distinguish antigen-dependent exhaustion from systemic exhaustion in HIV, 
we compared HIV-specific to CMV-specific CD8 T cells in our cohort. CMV is a common 
regularly controlled chronic human viral infection, besides occasional reactivation like other 
Herpesviridae. We found increased frequency and levels of TIGIT expression on HIV-
specific CD8 T cell responses compared to CMV-specific cells in each group (Fig. 4A). 
Thus, increased TIGIT expression is increased in an antigen-specific manner in HIV 
infection. In addition, treatment-naïve individuals had higher TIGIT expression on HIV-
specific CD8 T cells than ART treated PLHIV or elite controllers (Fig. 4A). As exhaustion is 
strongly driven by antigen, our results are in line with TIGIT playing a role in HIV-mediated 
T cell exhaustion. TIGIT was co-expressed with other inhibitory receptors, such as PD-1, 
2B4, and CD160, which further confirms expression on exhausted cells. 
We then further characterized cells expressing high levels of TIGIT. These cells were more 
common among HIV-specific compared to CMV-specific CD8 T cell responses within 
PLHIV. Compared to ART-naïve patients, who displayed a high proportion of CD107a single 
positive cells, elite controllers and ART-treated HIV infected individuals had more 
polyfunctional HIV-specific CD8 T cells. The frequency of TIGIThi HIV-specific CD8 T 
cells was correlated to the frequency of CD107a single positive cells and inversely correlated 
to the frequency of polyfunctional cells. This links high levels of TIGIT expression to 
functionally impaired cell populations. Furthermore, cells with high TIGIT expression more 
readily displayed a T-betdim/Eomeshi transcriptional profile, which is related to exhaustion 
(218, 299) and might be directly linked to TIGIT expression, as TIGIT can repress T-bet in 




Figure 4. TIGIT and CD226 expression on CMV- and HIV-specific CD8 T cells. Frequency of 
(A) TIGIT positive and (B) CD226 positive CD8 T cells specific for HIV or CMV. Cells from 
treatment naïve (HIV+ART-), ART treated (HIV+ART+) PLHIV and elite controllers (EC) were 
analyzed. (C) CD226 expression on virus-specific CD8 T cells with high (left) and 
intermediate/diminished (right) levels of TIGIT. Adapted from paper I. 
TIGIT is part of a signaling network by competing with CD226, a co-stimulator, for binding 
to PVR. We were able to show that CD226 expression was decreased on HIV-specific cells 
in comparison to CMV-specific CD8 T cells (Fig. 4B) and that lack of CD226 expression 
was especially linked to high levels of TIGIT (Fig. 4C). To predict the probability of HIV-
specific T cells to encounter the ligand PVR, we analyzed expression on CD4 T cells. We 
found that circulating and lymph node resident CD4 T cells in PLHIV express higher levels 
of PVR compared to healthy control subjects. Further, TFH in lymph nodes showed increased 
frequency and expression levels of PVR compared to memory CD4 T cells in circulation. 
Expression of PVR was also associated with activation of T cells. TFH were linked to residual 
replication despite ART (66). Inhibition of HIV-specific CD8 T cell responses in lymph 
nodes through the TIGIT/CD226/PVR network would thus further impair elimination of 
lingering HIV replication in treated PLHIV. However, we did not analyze whether the PVR 
expressing CD4 T cells are infected and data on the influence of HIV on PVR expression are 

























































































































(301). An additional barrier is the location of TFH inside lymphoid follicles, as CD8 T cells do 
not enter these sites of HIV replication (302, 303).  
4.1.2 TIGIT/PD-1 co-expression is delayed in HLA-B*57 restricted responses 
To investigate the influence of the protective allele HLA-B*57:01 on exhaustion of HIV-
specific CD8 T cell responses, we investigated a cohort of untreated PLHIV for paper II. We 
compared HIV infected study participants with and without this protective HLA allele and 
analyzed longitudinal samples, starting after completion of the acute stage and monitoring 
treatment-free progression. To ensure that differences in progression were not linked to viral 
dynamics, we confirmed that viral evolution was indeed comparable between the patient 
groups. 
Subtle differences in functionality revealed trends toward higher polyfunctionality in HLA-
B*57-restricted CD8 T cell responses, while HIV-specific responses restricted by other HLA 
alleles tended to have more single expression of either CD107a or IFNγ than their 
counterparts. In line with waning ability to maintain immune functions over the course of 
HIV infection, HIV-specific responses from HLA-B*57-negative participants displayed 
decreased expression of granzyme A over the time of infection. For this study, we selected 
participants with similar disease progression in both groups. Thus, the increase of CD107a 
expression among HLA-B*57-restricted CD8 T cell responses reflects the assimilation of 
clinical characteristics at later time points. In agreement, expression of all inhibitory receptors 
studied (2B4, CD160, KLRG-1, PD-1 and TIGIT) increased among HLA-B*57-restricted 
CD8 T cell responses, and 2B4 and KLRG-1 expression increased among responses restricted 
by other alleles (Fig. 5A). 
The main finding of this project was the difference in co-expression of TIGIT and PD-1 (Fig. 
5 A-C). In early chronic infection, HLA-B*57-restricted responses had a lower proportion of 
TIGIT+PD-1+ double positive cells compared to responses restricted by other alleles (Fig. 5 
B-C). This co-expression was also associated with disease progression in the form of CD4 T 
cell depletion and higher viral loads. The stronger correlation with CD4 T cell depletion 
compared to viral loads might directly or indirectly link exhaustion to the quality of CD4 T 
cell help rather than viremia. In accordance with progression towards AIDS, the proportion of 
TIGIT+PD-1+ double positive HLA-B*57-restricted and non-HLA-B*57-restricted CD8 T 




Figure 5. TIGIT/PD-1 co-expression in early chronic infection of PLHIV positive and negative 
for HLA-B*57:01. Frequency of (A) 2B4, CD160, KLRG-1, PD-1, and TIGIT expression and (B) 
PD-1/TIGIT co-expression on HIV-specific CD8 T cells restricted by HLA-B*57 (turquoise) or other 
alleles (orange). (C) Examples of PD-1 and TIGIT co-expression on memory CD8 T cells (grey 
background) and HIV epitope-specific responses (overlayed red dot plot). Adapted from paper II. 
4.2 SYSTEMIC IMMUNE DETERIORATION IN HIV-1 AND HIV-2 
Independent of antigen-specific immune responses, the immune system of PLHIV is 
chronically subjected to systemically increased levels of proinflammatory signals and 
counteracting mechanisms in order to minimize tissue damage. This leads to immune 
pathogenesis in a more systemic manner than that described for HIV-specific CD8 T cells in 
the previous section, as a multitude of cell types and anatomic structures are affected. 
4.2.1 TIGIT on bulk CD8 T cells 
We analyzed bulk CD8 T cells in paper I to describe the effects independent of chronic 
TCR-mediated interactions. We linked TIGIT expression to T cell differentiation and 
comparing it to PD-1 expression. We saw that TIGIT was more broadly expressed than PD-1 
and that most PD-1 positive cells were also expressing TIGIT, but not vice versa. The 
expression of TIGIT by bulk CD8 T cells followed a hierarchy reminiscent of disease 
progression, in which the proportions increased from seronegative control subjects and acute 
infection, to elite controllers, long-term ART treated and was highest in treatment-naïve 
chronic infection. 
We were also able to perform longitudinal analysis of TIGIT expression in patients initiating 
ART during acute or chronic infection. Follow-up after six months revealed that both the 
frequency, as well as the expression level of TIGIT increased despite early initiation of ART. 
Post one year of ART initiation, patients with early initiation had similar TIGIT expression 
 
 39 
on bulk CD8 T cells as patients initiating treatment during the chronic stage. This reinforces 
previous studies showing that prevention of CD8 T cell exhaustion is not improved with early 
initiation of ART except if treatment is started before seroconversion (304). 
The association of TIGIT expression with accumulation of multiple immune checkpoints 
(PD-1, CD160, 2B4) as well as the T-betdim/Eomeshi transcription profile was also observed 
on bulk CD8 T cells. Thus, TIGIT is not only implicated in antigen driven exhaustion, but 
also systemic immune deterioration of CD8 T cells in HIV-1 infection. 
4.2.2 CD8 T cell phenotypes in HIV-2 
In HIV-2, the proportion of infected individuals controlling viral replication while staying off 
treatment is significantly higher, while individuals with viremia experience disease 
progression comparable to HIV-1 infection. To evaluate the influence of viremia on T cell 
exhaustion and activation in relation to HIV-1 and HIV-2, a cohort of police staff from 
Guinea-Bissau (305) regularly screened for HIV infection was analyzed (paper III). The 
cohort allowed for recruitment independent of clinical symptoms and comparison of CD8 T 
cells between viremic and aviremic HIV-2 infection without ART. In addition, control groups 
comprised treatment-naïve and treated HIV-1 infected and HIV-seronegative individuals.  
Late-differentiated memory CD8 T cells skewed towards an activated and highly exhausted 
phenotype were more frequent in untreated HIV-1 compared to HIV-2, treated compared to 
untreated HIV-1, and viremic compared to aviremic HIV-2. Further analysis confirmed that 
combined expression of activation (CD38 and HLA-DR) and exhaustion (2B4, PD-1 and 
TIGIT) markers was associated with disease progression in the form of CD4 T cell depletion 
and VL. We observed the highest frequencies of activated/exhausted cells in viremic HIV-2 
infection and that aviremic HIV-2 infection displayed increased T cell pathogenesis in 
comparison to seronegative individuals. The main causes of T cell exhaustion are viral 
replication and the consequential inflammation. Our results confirm this link, but also 
highlights that aviremic HIV-2 infection impacts CD8 T cells despite viral control, potentially 
through replication below the detection limit. 
Subsequently, we analyzed co-expression of activation markers and CD226. Cells without 
signs of activation but expressing the co-stimulator CD226 were decreased in both aviremic 
and viremic HIV-2 infection, while activated cells lacking CD226 were increased in both 
infected groups when compared to seronegative individuals. This suggests a diminished pool 





Figure 6. Skewing of CD8 T cells towards an exhausted phenotype in HIV-2 infection despite 
natural control. (A) Frequency of co-stimulation receptive (2B4+PD-1-TIGIT-CD226+) and highly 
exhausted (2B4+PD-1+TIGIT+CD226-) CD8 T cells, and (B) expression patterns of TIGIT and 
CD226 on CD8 T cells in HIV seronegative control subjects as well as aviremic and viremic HIV-2 
infection. Adapted from paper III. 
Due to the dual role of 2B4 as both an inhibitory and co-stimulatory receptor, we assessed the 
receptiveness to co-stimulation by combining expression patterns of CD226 and 2B4 with the 
exhaustion markers PD-1 and TIGIT (Fig. 6A). CD8 T cells expressing 2B4 and CD226, thus 
potentially receptive to co-stimulation, were decreased and cells expressing 2B4, PD-1 and 
TIGIT, a highly exhausted population, were increased in aviremic HIV-2 infection compared 
to seronegative study participants. Lastly, we focused on co-expression of TIGIT and CD226 
(Fig. 6B). We found that the frequency of CD226-TIGIT+ cells was increased and 
CD226+TIGIT- was decreased in both aviremic and viremic HIV-2 when compared to 
seronegative individuals. This further confirmed the skewed phenotype of bulk CD8 T cells 
towards exhaustion and reduced co-stimulation receptiveness in HIV-2 infection independent 
of viremia. As CD8 T cells require CD226 for activation by non-professional APCs (209), the 
skewing the TIGIT/CD226/PVR network on bulk CD8 T cells could have extensive impact 
on viral co-infections and malignancies in HIV-2 infection. 
4.2.3 Inflammatory markers in pediatric HIV-1 infection 
For paper IV, we aimed to identify the effects of current ART in pediatric HIV-1 infection 
on biomarkers associated with immune reconstitution and inflammation. The overall goal of 














































































































this project is to identify if there is potential for treatment optimization of HIV infected 
children in Sweden. 
Ligands of CCR5, the main co-receptor in HIV infection, are of interest due to their 
suppressive impact on HIV infection (154, 157) and their function as proinflammatory 
chemokines. Of the CCR5 ligands analyzed in this project, MIP-1β and RANTES, had 
comparable plasma concentrations in vertically HIV infected and seronegative children, and 
MIP-1α showed a slight trend toward lower concentration in infected children. Both MIP-1α 
and MIP-1β were decreased in vertically infected adolescents compared to vertically infected 
children and RANTES was reduced in HIV infected adults compared to vertically infected 
children. In line with this, the concentrations of MIP-1α and MIP-1β decrease with age in 
both children and adolescents, while RANTES decreases during adolescence. As we found 
no significant difference between HIV infected and seronegative children, this suggests 
higher levels of chemokines in children compared to adults. In addition to their potential to 
compete with HIV for binding to CCR5, MIP-1α, MIP-1β and RANTES are also 
proinflammatory chemokines. Successful viral suppression achieved with ART might shift 
the predominant effects from competition with HIV entry to promoting chronic inflammation. 
MIP-1β is associated with unsuccessful increase in CD4 T cell counts after ART 
initiation(160) and MIP-1α affects lipid metabolism (161) and thus cardiovascular 
comorbidities. 
Another biomarker, sTRAIL, has a role in cell death and is thus involved in depletion of both 
infected and uninfected CD4 T cells in HIV infection (166, 170). The plasma concentration 
of sTRAIL was the only statistically significant difference between HIV infected and 
seronegative children in our cohort (Fig. 7 A). Plasma concentrations of sTRAIL were higher 
in HIV infected children, but decreased with age in infected children and adolescents, which 
was confirmed with lower concentrations in HIV infected adolescents when compared to 




Figure 7. Plasma concentration of sTRAIL in vertically infected children and adolsecents, as 
well as HIV seronegative children. 
TRAIL exists in several forms: membrane bound, soluble and as the non-functional splice 
variant, TRAILshort. Reduced expression of TRAILshort in elite controllers diminishes 
inhibition of the functional forms of TRAIL (306), thus links increase in TRAIL to virus 
control. This suggests an advantage for HIV infected children through increased sTRAIL 
concentrations. However, the close link to CD4 depletion together with the fact that viremia 
is suppressed in the majority of our patients, could mean that the pathogenic role of sTRAIL 
predominates. 
The role of cytokines and chemokines is often ambiguous, as they have the potential to 
increase both, functional immune responses against HIV, as well as the immune activation 
underlying comorbidities and complications. Factors such as the anatomical and cellular 
source of the proteins determine which of the two effects outweighs the other. 
In contrast to other markers evaluated in this project, sCD14 is the result of microbial 
translocation, but has only minimal impact on HIV-specific responses. In our cohort, sCD14 
was higher in HIV infected children compared to HIV infected adults, but lower than in HIV 
negative children, though this difference was not statistically significant. This contrasts 
earlier studies that found increased sCD14 levels in HIV infected children older than 2 years 
(307). However, it is important to note, that microbial translocation or a “leaky gut” is the 
physiological norm in infants and gut barrier function is not fully developed until the age of 
two years (308). Thus interactions between the developing gut barrier and mucosal immune 
system with HIV and timing of treatment initiation might affect concentrations of CD14 in a 
durable manner. 
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Fortunately, vertical infection is very rare in Sweden and most pediatric HIV patients have 
been infected prior to their arrival to Sweden. However, this results in a large heterogeneity 
of both patients (regarding ethnicity, age of diagnosis and ART regimen in their country of 
birth) and virus (e.g. higher frequency of HIV clades like HIV-1C that are rare in adult 
Swedish risk groups) within a small patient cohort. The limitations with regards to size and 
heterogeneity of our cohort probably contribute to the lack of statistically significant findings 
in this analysis. However, vertically HIV infected children and adolescents in Sweden are 
well treated and monitored closely, which is the main reason for the minimal differences 





5 CONCLUSIONS & PERSPECTIVES 
5.1 HIV-SPECIFIC CD8 T CELL RESPONSES 
We showed that TIGIT, especially when expressed at high levels or co-expressed with PD-1, 
has an important role in exhaustion of HIV-specific CD8 T cells (paper I and II). High 
levels of TIGIT as well as TIGIT/PD-1 co-expression correlate with impaired functionality of 
HIV-specific CD8 T cells and an exhausted transcription factor profile. HIV infection was 
previously linked degranulation of vesicles devoid of cytokines or cytotoxic molecules and 
consequential incapability to eliminate HIV infected cells (216). We observed that TIGIT 
expression was associated with this particular defect. In contrast, elite controllers showed 
reduced frequency and levels of TIGIT expression, and the protective HLA allele HLA-B*57 
can delay TIGIT/PD-1 co-expression. Furthermore, ART can slow down, but not prevent 
upregulation of TIGIT.  
T cell exhaustion is an alternative differentiation path, deviating from effector and memory 
fates, and is thus detectable in lasting changes to the transcription factor profile. Previous 
studies linked downregulation of T-bet and upregulation of Eomes, resulting in a T-
betdim/Eomeshi profile, to CD8 T cell exhaustion (218). We were able to show the association 
of high TIGIT expression on HIV-specific CD8 T cells with T-betdim/Eomeshi (paper I). 
More recently, early differentiation events towards an exhausted T cell fate have been linked 
to TOX (219) and TCF-1 (309). The size and maintenance of this progenitor pool might have 
direct implications in immune deterioration and thus disease progression in HIV. 
Maintenance of a larger progenitor pool with improved proliferative capacity could maintain 
a larger frequency of early differentiated immune responses with at least partial 
polyfunctionality. Alternatively, increased differentiation towards an exhausted fate might 
suppress other differentiation paths, thus limiting memory and effector T cells. The frequency 
of TOX and TCF-1 expression among HIV-specific CD8 T cells, especially in treatment 
naïve PLHIV with different disease progression could give insight into the role of this 
progenitor pool in HIV infection. 
A number of factors influence T cell exhaustion, prominent among those are the quantity and 
quality of CD4 T cell help and duration and level of antigen exposure. In accordance, we 
were able to show that successful treatment and thus reduction in antigen treatment can slow 
down, however not prevent nor fully reverse, CD8 T cell exhaustion. Furthermore, elite 
controllers, a small group of PLHIV with natural suppression of viral replication and 
maintained CD4 T cell levels, show reduced frequency and levels of TIGIT expression. 
Among host genes, HLA alleles are among the strongest contributors to the rate of disease 
progression (221). In addition to factors like the targeting of specific epitopes, protection by 
HLA alleles was also linked to the ability to establish new responses targeting emerging viral 
mutations and the ability to produce IL-2 (214). Here, we showed that the partial protection 
of HLA-B*57 in the context of HIV infection also extends to a delay in CD8 T cell 
exhaustion (paper II). 
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As HIV targets CD4 T cells, it creates a pathogenic cycle in which elimination of HIV 
infected cells does simultaneously curb viral replication, but also diminish CD4 T cell help 
and thus fuel exhaustion. Checkpoint blockade targeting receptors such as TIGIT and PD-1 
could potentially counteract this immunopathogenesis, as theorized in “shock and kill” 
strategies (279). However, data on PD-1 indicate that blockade is only effective on cells with 
intermediate, not high expression levels of PD-1 (204, 205), and efficacy of TIGIT blockade 
requires expression of CD226 (310). Our data indicate that reinvigorating existing and 
preventing advanced exhaustion of novel HIV-specific responses will be blunted by the 
frequency of cells expressing high levels of inhibitory receptors as well as skewing of entire 
signaling networks, as observed in the downregulation of CD226 and simultaneous 
upregulation of PVR in this context. 
Detailed knowledge of exhaustion markers and how their expression patterns are linked to the 
severity of the deterioration can be utilized in monitoring vaccines and therapies under 
development. Different vectors, adjuvants and administration strategies might influence not 
only the development of HIV-specific responses upon vaccination but might also determine 
their maintenance. 
5.2 SYSTEMIC IMMUNE DETERIORATION 
We found dysregulation of bulk CD8 T cells in the form of a skewed TIGIT/CD226/PVR 
network in ART treated HIV, including PLHIV who started ART early (paper I) and in 
natural control of HIV-2 infection (paper III). Further impairment of co-stimulation and 
exacerbation of inhibition in combination with CD8 T cell activation was seen in aviremic 
HIV-2 infection (paper III). Lastly, progressive upregulation of TIGIT and PD-1 in HLA-
B*57 positive PLHIV, but consistently high expression in the absence of HLA-B*57 shows a 
link between exhaustion and the partial protection mediated by this HLA allele (paper II). 
Together, our results suggest extensive pathogenic changes to the bulk CD8 T cell pool in 
HIV infection, spanning ART mediated and natural control, as well as HIV types. TIGIT is 
one of the key players in this deterioration through competition with CD226, synergy with 
PD-1 and correlation with the expression of other inhibitory receptors. 
The dysregulation of CD8 T cells documented in HIV-2 infection (paper III) included 
expression of 2B4 either in concert with CD226 or along with TIGIT and PD-1. The 
contradictory functions of 2B4 as an inhibitory or co-stimulatory receptor (212) and the 
potential synergy with CD226 (213) imply functional consequences of this expression 
pattern. However, these studies regarding 2B4 have been performed on other cell types. 
Functional studies regarding 2B4 co-expression patterns on CD8 T cells would allow for 
better interpretation of our results. 
The CD8 T cell exhaustion pattern identified in our cohorts supports their biological 
relevance for underlying complications such as higher risk of cancer, loss of control over 
chronic infections or reduced protection by vaccinations. The impact on the immune system 
at large and diminished quality of CD8 T cells in particular will also need to be considered 
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when attempting immunotherapies to ameliorate said complications. Checkpoint blockade 
affects novel T cell responses (311), thus efficacy depends on the availability and quality of 
bulk CD8 T cells, and adoptively transferred CAR T cells depend on the quality of the T cell 
pool used (312). The skewing of the TIGIT/CD226/PVR network along with the co-
expression with other inhibitors implies that additional efforts, such as stimulation of CD226 
expression, will be necessary in PLHIV to achieve outcomes comparable to HIV negative 
patients. 
The immunopathogenesis in HIV-2 despite natural control of viral replication is reminiscent 
of HIV-1 LTNPs and ECs. Maintenance of this viral suppression requires immune activation 
and might thus be the cause for the limited immune deterioration that still persists in 
comparison to the seronegative population. However, ECs still have a higher risk of non-
AIDS complications and treatment despite viral control has been suggested for this group of 
PLHIV (313). Similarly, we suggest that treatment of HIV-2 infection despite natural control 
might curb immune deterioration in this population. 
In paper IV, we evaluated plasma biomarkers in vertically infected children and adolescents. 
The quality of medical care in Sweden results in limited differences between HIV infected 
children in comparison to HIV negative children. A more thorough investigation by focusing 
on the candidates found in this project might reveal targets for optimization. Alternative 
forms of the investigated biomarkers (e.g. TRAILshort in comparison to sTRAIL), their 
cellular sources and receptors on key cell types impacted will allow stronger conclusions. To 
expand our analysis, T cell pathogenesis will be analyzed by flow cytometry. Both functional 
aspects, such as cytokine production and proliferative capacity, and phenotypic changes, 
regarding exhaustion marker expression and CD4 and CD8 T cell subsets, will be included in 
this characterization. 
To alleviate the burden of comorbidities in treated PLHIV, several approaches have already 
entered clinical trials in adult patients (251). However, many of those will not be applicable 
to children. First and foremost, the reduction of triple combination ART to a regimen of two 
drugs might lead to even higher complications in children, as they are already at higher risk 
of virological failure. Compounds such as statins, which lower inflammation via reduction of 
cholesterol, operate indirectly and their primary effects need to be considered thoroughly. 
Thus, new candidates for targeted therapies specific to HIV infected children might be 
necessary to improve treatment outcome in this cohort. 
5.3 CONCLUDING REMARKS 
Systemic immune deterioration seen in HIV infection is the driver of disease and has 
implications both directly on HIV/AIDS, but also on numerous non-AIDS complications. 
Modern immunomodulatory therapies have opened the door to use our knowledge on 
immune responses in a therapeutic way. While direct use of immunotherapies against HIV is 
still restricted to preclinical research, the severe side effects accepted in some cancer patients 
are not considered ethically justified in well treated PLHIV. However, increased risk of 
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malignancies in PLHIV and expansion of applications of immunotherapies will increase the 
likelihood for PLHIV to be considered for this type of therapy in one way or another. 
Detailed knowledge of immune deterioration and exhaustion in HIV might thus guide care 
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